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ABSTRACT
Soft poly-ethylene-glycol (PEG)-based soft nanoparticles (NPs) including cylindrical (CNPs)
micelles, spherical (SNPs) micelles, and lipid bilayer vesicles (LNPs) are thought to be treated as
foreign objects by mammalian phagocytes. If this hypothesis is true, NPs should trigger a proinflammatory, autophagic phenotype that is similar to the one seen when macrophages
phagocytose pathogens or when macrophage surface expressed proteins bind pathogen surface
factors such as lipopolysaccharide (LPS). Here, we show that macrophage responses to the above
NPs are almost completely unique from those triggered by group A streptococcus (GAS)
pathogens (JRS4 cells) and LPS. Instead, macrophages treat these soft NPs more like high-density
lipoprotein (HDL) and low-density lipoprotein (LDL). RNA sequencing of macrophage transcripts
after hHDL, hLDL, JRS4 cell, LPS, and LNP incubation showed three diverse response clusters
triggered by JRS4 cells, LPS, and hHDL-hLDL-LNP-PBS.
Of these reagents, LNPs triggered the fewest post-incubation transcript changes from macrophages
to which PBS was added (control). LNPs did not increased the transcription of factors associated
with foreign object identification including Fc and complement receptors. LNPs did not increase
transcripts whose translated proteins are involved in phagocytosis, autophagy, lysosome
biogenesis, or inflammation. LNPs did not increase Tfeb transcripts, which is a master regulator
of lysosome biogenesis and a necessary component of autophagy. To further determine the effects
of these NPs on cells, we performed fluorescence microscopy and flow cytometry experiments.
CNPs, SNPs, and LNPs lowered macrophage autophagosome levels that were raised by the
canonical challenges: starvation, rapamycin, and LPS. CNPs, SNPs, and LNPs lowered reaction
oxygen species (ROS) levels, did not increase lysosome acidification, and the reduced the secretion
of pro-inflammatory cytokines compared to basal conditions and LPS addition to macrophage
cultures. CNPs and SNPs triggered low lysosome acidification and LNPs did not increase Tfeb
levels, the master regulator of lysosome biogenesis and a necessary component of autophagy.
Thus, the terminology that macrophages “clear” NPs, which has been used over many decades, is
most likely misleading. Our findings challenge the hypothesis that the main uptake mechanism of
soft PEG-NPs by M1-polarized murine macrophages in vitro is phagocytosis.
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CHAPTER 1
THE ROLE OF AUTOPHAGY IN CANCER CHEMOTHERAPY DRUG RESISTANCE

This chapter is based on the published paper:
Asoudeh, M.; Dalhaimer, P. D.; The role of autophagy in cancer chemotherapy drug
resistance. Scientific Letters. 2022, Volume I (1), https://doi.org/10.48797/sl.2022.10.
Introduction
Tumor cells can become resistant to chemotherapy drugs [1]. At the gross anatomy scale, resistance
is due mainly to the limited amount of drug that can be administered to a patient because of toxicity
[2]. Thus, cells deep in tumors are usually exposed to less-than-lethal doses of drug that do not kill
them. By being exposed to low doses of a chemical, the surviving cells become resistant through
a variety of mechanisms. A key question is how this resistance occurs on the cellular and molecular
levels. Answers to this question can be found, in part, in the cellular response mechanism
autophagy. Autophagy is a conserved process that engulfs and degrades either seemingly random
areas of the cytosol or targeted proteins and organelles [3]. The material to be broken down is
engulfed in a double membrane structure that matures from the ER as an omegasome, grows into
a phagophore, which then elongates into an autophagosome [4]. The autophagosome surrounds its
cargo and then merges with a lysosome to form an autolysosome [5]. The contents of the
autolysosome are degraded, and their fundamental moieties are reused [6] A comprehensive guide
to the molecular mechanisms of autophagy has been recently published [7].
Autophagy plays at least two roles in cancer progression and cancer chemotherapy drug resistance.
First, it keeps eukaryotic cells alive in times of nutrient deprivation. Since cancer cells need

reagents for unregulated growth, autophagy helps them thrive when nutrients are scarce. Second,
certain chemotherapy drugs cause the generation of reactive oxygen species (ROS). ROS in turn
triggers autophagy. This also helps keep cancer cells alive. The goal of this review is to highlight
the effects of a subset of cancer chemotherapy treatments on ROS and autophagy that were
reported in recent years. More than one-third of the references are from studies within the last five
years. We focus mainly on the mechanisms by which chemotherapy drugs alter the states of
1

proteins involved in the ROS-autophagy axis and provide a glimpse of the possibilities of cotreatments of anti-cancer and anti-autophagy agents.

Autophagy
Initiation of autophagy involves the formation of two protein complexes, the serine/threonine
kinase ULK1 complex and the class III PI 3-kinase complex 1 (PI3KC3-C1) (Fig. 1.1) [7,8]. Under
nutrient deprivation, phosphoinositide 3-kinase class 1 (PI3K1) turns on a signaling cascade
involving protein kinase B (Akt) that inhibits mTOR and ultimately activates ULK1-mediated
ULK1/ATG13/FIP200 dephosphorylation [9,10]. ULK1/ATG13/FIP200 complex cooperates with
Beclin-1/PI3KC3/Vps34 and promotes phagophore nucleation. Activation of Beclin-1/PI3KC3
leads to hydrogen peroxide (H2O2) accumulation in mitochondria because of stress conditions and
nutrition deprivation, ultimately leading to the generation of ROS [11]. ROS further induces
autophagy through several pathways [11]. These include AMPK activation, which leads to the
activation of the ULK1/ATG13/FIP200 complex.
The term autophagy encompasses a broad class of cellular responses. One classification strategy
is for autophagy to be described as selective or non-selective. In the former, organelles and
pathogens are directly targeted for degradation. In this form of autophagy, cargo adaptor proteins
Sequestosome 1 (SQSTM1)/p62, neighbor of BRCA1 gene 1 (NBR1), or B-cell lymphoma 2 (Bcl2)/adenovirus E1B 19-kDa-interacting protein 3 longform (NIX/BNIP3L) bind both the cargo and
ATG8 family proteins such as LC3 and GABARAP, which are on the phagophore [12–15]. In the
latter, volumes of the cytosol are engulfed and recycled. We focus on the subsets of autophagy that
have been found to be important in cancer cells, with ROS-induced autophagy at the forefront. It
is mechanistically unclear if ROS generates selective, non-selective, or both types of autophagy
[16].

Reactive Oxygen Species (ROS)
ROS are unstable, partially reduced oxygen derivatives, which are byproducts of metabolic
processes. They are continually being generated during normal metabolic processes [17]. They
include hydrogen peroxide (H2O2), superoxide anion (O2-), hypochlorous acid (HClO), singlet
2

Figure 1.1. Proteins involved in autophagy initiation, phagophore formation, elongation and autophagosome
formation. Autophagy and ROS levels are positively correlated.
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oxygen (1O2), and hydroxyl radical (·OH) [18]. ROS-producing enzymes include NADPH
oxidases, cyclooxygenases (COX), and lipoxygenases (LOX). ROS are generated from oxygen
mostly in mitochondria during oxidative phosphorylation [19,20]. Peroxisomes generate superoxide
and H2O2, contributing to ROS production. Chemotherapy drugs also contribute to ROS
production, as discussed below.

ROS Regulates Autophagy
The main downstream autophagic effectors of ROS are ATG4 (at Cys-81) AMP-activated protein
kinase (AMPK), ULK1/ATG1 (through AMPK), and the transcription factor NF-kB, which leads
to the expression of Beclin-1 and SQSTM1/p62 [11,21–26]. ATG4 oxidized by ROS at specific
cysteine residues is unable to delipidate LC3 [27,28]. Since lipidated LC3 is part of the
autophagosome, ROS interaction with ATG4 leads to the sustained presence of autophagosomes
[21]. Because mitochondria produce ROS, autophagy of mitochondria, a process called mitophagy,
is crucial for regulating ROS levels. Mitophagy initiation involves either the ubiquitin-mediated
PINK1-Parkin pathway or the receptor-mediated FUNDC1/BNIP3/NIX pathway[29]. In the
former, PINK1 accumulates in the outer mitochondrial membrane [30]. A phosphorylation cascade
involving PINK1 and Parkin activates Parkin’s ubiquitin ligase activity [31]. Parkin then
ubiquitylates outer mitochondrial membrane proteins Mfn1, Mfn2, VDAC, and MIRO1 [32].
Ubiquitinated proteins are then recognized by ATG8-family junction proteins SQSTM1/P62,
OPTN, NDP52, TAX1BP1, and NBR1. Interestingly, PINK1-PRKN-dependent mitophagy
requires GABARAP, not LC3 [33,34]. The phagophore then nucleates around the damaged
mitochondria and autophagy is initiated. In the latter case, the mitochondrial receptor proteins
FUNDC1, BNIP3, NIX, FKBP8, Bcl2L13, Ambra1, PHB2, and NLRX1 contain a conserved LC3interacting receptor domain that can bind LC3 and thus be engulfed in a developing
autophagosome [35–43].

ROS in Cancer Cells
Cancer cells have high ROS levels [44]. This is due mainly to augmented cell proliferation,
differentiation, protein synthesis, glucose metabolism, and inflammation [45]. Increased
4

metabolism in cancer cells results in respiratory dysfunction and electron leakage from
mitochondria [46]. In fact, cancer cells often have dysfunctional mitochondria. ROS levels can
further increase by oncogene activation, or cytokine/growth factor signaling [28,47]. During ROSinduced tumor cell progression, ROS activates the Wnt signaling pathway. Wnt activation leads to
the epithelial-mesenchymal transition [48]. It also upregulates the transcription factor c-Myc [49].
Overexpression of c-Myc is a hallmark of cervical carcinomas, leukemias, lymphomas, colon, and
testicular cancer [50,51]. In turn, c-Myc overexpression can generate additional ROS [52]. With this
background in autophagy and ROS, we now focus on the mechanisms by which chemotherapy
drugs trigger additional ROS production, which in turn triggers pro-survival autophagy in cancer
cells.

Autophagy plays different roles in cancer cells depending on the stage of tumor progression [53].
Autophagy can help reduce the probability of DNA mutations by suppressing ROS in the early
stages of oxidative cell stress [54]. This occurs mainly through mitophagy. In primary tumor cells,
autophagy can cause p53-dependent apoptosis, thus preventing accumulation of oncogenic p62
protein aggregates and metastasis [55]. p53 plays pro- and anti-autophagic roles depending on its
localization in cells [56]. p53 is usually localized to the cytosol. Cytosolic p53 suppresses
autophagosome formation by interacting with FIP200, which leads to inhibition of
ULK1/Atg13/FIP200 complex [56]. When p53 translocates to the nucleus, it initiates autophagy.
In the nucleus, p53 activates autophagy inducers, including DRAM1 and Sestrin2 [57]. In these
cells, downregulation of BCL-2/BCL-xl induces pro-apoptotic autophagy [58]. At this point in
cancer progression, when cells are adapting to stress (e.g., nutrient deprivation, hypoxia, metabolic
stress, and chemotherapy), autophagy reduces both DNA and ROS damage, and removes damaged
organelles [59]. In metastasis, autophagy helps migrating cells overcome hypoxia, nutrient
deprivation, and autophagic gene mutation that leads to chemotherapy resistance [55]. Thus,
depending on the stage of the cancer, with more advanced cancers needing more nutrients, cancer
cells should naturally trigger ROS production [60].

5

The Effects of Chemotherapy on ROS Production
Chemotherapy can cause ROS generation by disrupting and/or by inhibiting the cellular
antioxidant system [61–67]. In the former, chemotherapy drugs can destabilize mitochondrial
membranes, disrupting the mitochondrial electron transport chain. This leads to electron leakage,
which elevates ROS production [61–63]. Thus, mitophagy could play a central role in chemotherapy
drug resistance. In the latter, chemotherapy agents can cause the depletion of antioxidants such as
glutathione (GSH) and the superoxide dismutase (SOD) enzyme [65,66].
Since autophagy can sustain cell viability, it is important to determine if there are functional
overlaps or interactions with autophagy gene products and the anti-apoptotic proteins that cancer
cells use for survival [68]. BCL-2 family members are a prominent class of anti-apoptotic genes
[69]. During stress conditions, Beclin-1 interacts with BCL-2/xl/w/MCL-1, thereby activating
autophagy via the interaction of Beclin-1 with Vps15 and Vps34 [70]. (Figure 1.2) This complex
promotes phagophore nucleation [69]. Thus, we see that anti-apoptotic genes work with autophagy
genes to maintain cell viability. However, BCL-2 proteins can also be apoptotic. BCL-2, BCL-xl,
BCL-w, and MCL-1 inhibit survival autophagy when BCL-2 interacts with Beclin-1. This complex
blocks the action of Bax/Bak1 [69]. Activated Bax/Bak1 complex causes mitochondrial membrane
permeabilization and rupture by interacting with ceramide channel-forming sphingolipid or form
putative cytochrome c release channels on the outer membrane of mitochondria to induce
permeabilization [71].

Certain Chemotherapy Drugs Cause Autophagy
The main link between cancer chemotherapy drug resistance and autophagy is that drugs trigger
ROS production, which triggers autophagy, keeping certain cancer cells viable. Table 1.1
summarized drugs that are involved in chemotherapy treatments that trigger autophagic pathways.
Piperlongumine. Piperlongumine is used as an anti-cancer drug for lung, breast, prostate, and
gastric cancers. Piperlongumine causes p38 and JNK phosphorylation via a ROS-dependent
pathway. This leads to increased expression of Bax and Beclin-1 [72,73]. It also inhibits Akt/mTOR
phosphorylation, triggering autophagy. Piperlongumine activation of p38 inhibits ATG5 and the
formation of autophagosomes (Figure 1.3). In piperlongumine-treated androgen-independent
6

Figure 1.2. Different functions of BCL-2 family members. Beclin1 dissociation from BCL-2, BCL-xl, BCL-w,
MCL-1 during the stress conditions causes phagophore nucleation and triggers autophagy. While, Pro-apoptotic
BCL-2 (Bax and Bak1) causes mitochondrial membrane rupture. Cell survival genes coordinate with autophagic
genes to promote viability.
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Table 1.1. Drugs and their effect on autophagy. MM: multiple myeloma; HCC: hepatocellular carcinoma cancer;
HER2: Human epidermal growth factor receptor 2; ROS: reactive oxidative species; Caspases: cysteine-dependent
aspartate-directed proteases; DOX: Doxorubicin; PI3K1: phosphoinositide 3-kinase class 1; mTOR: mechanistic
target of rapamycin [serine/threonine kinase]; Akt: A serine/threonine kinase; AMPK: adenosine monophosphateactivated kinase;
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Figure 1.3. Role of piperlongumine in the autophagic pathway. Piperlongumine activates p38 phosphorylation
leading to autophagosome formation. It also triggers autophagy via ROS promotion and Akt/mTOR inhibition.
Piperlongumine also phosphorylates JNK leading to the triggering of apoptosis by Bax and Beclin-1.
Piperlongumine triggers a combination of autophagic and apoptotic pathways.
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human PC-3 prostate cancer cells and renal carcinoma 786-O cells, stimulation of ROS inhibits
the phosphorylation of Akt [74].
Sorafenib. Sorafenib inhibits protein kinases including VEGFR, PDGFR, and RAF [84].
Rodríguez-Hernández et al. have shown that a low dose of sorafenib, a drug to treat advanced
hepatocellular carcinoma (HCC), increased autophagy in HepG2 liver cells in vitro [75,85] The
survival role of autophagy has been seen in lower doses of sorafenib through activation of caspase9 [75]. Caspase-9 is activated by adenosine uptake into mammalian cells followed by conversion
to AMP, and ultimately AMPK activation 86]. In contrast, higher doses of sorafenib induced cell
death through caspase-3 pathway by inhibiting BCL-2 family proteins [85]. (Figure 1.4) FOXO3a
is an important transcriptional factor which is regulating stress responses such as hypoxia and
nutrition depravation in the cells. Phosphorylation of FOXO3a occurs under starvation condition
via PI3K-AKT signaling pathway [87]. mTOR is upregulated by sustained sorafenib and AKT
activation therefore, it leads to autophagy induction and cell apoptosis [88]. FOXO3a knockout
inhibits hypoxic induced autophagy so to eliminate the sorafenib resistance FOXO3a plays a
pivotal role in HCC cells [89].
miRNAs and lncRNAs. MicroRNAs (miRNAs) are non-coding RNAs that regulate gene
expression, cell proliferation, and apoptosis [90]. miRNAs are involved in the initiation,
progression, and drug resistance of HCC [91]. Similarly, miR-212 downregulates lethal autophagy
through the Akt/PTEN pathway in sorafenib‐resistant cells [92]. Xie et al. have confirmed the
downregulation of the AKT/PTEN/NF-kB signaling pathway by miR-132, which blocks resistance
by doxorubicin (DOX) in HCC cells [93,94]. miR-132 targets PIK3 regulatory subunit 3 (PIK3R3)
and inhibits autophagy and drug resistance in HCC cells [95]. Also, miR-223 overexpression
induced non-lethal autophagy in cisplatin-resistant cells; therefore, miR-223 inhibition enhanced
cisplatin efficacy in vivo [96]. In another example of HCC treatment, it was shown that cisplatin-

induced downregulation of miR-199a-5p increased drug resistance by activating AGT7, another
autophagy associated gene that interacts with LC3 [89]. (Figure 1.5) miR-22 increases the
sensitivity of osteosarcoma cells to cisplatin [97]. An miR-22 mimic that was transfected into
osteosarcoma cells downregulated ATG5, beclin1, and LC3 [98]. Thus, miR-22 may improve
cisplatin sensitivity by inhibiting autophagy. This is an example where the combination of anticancer drugs and autophagy modulators may improve chemotherapy treatment outcomes.
11

Figure 1.4. Role of sorafenib in autophagic pathway. The extent of autophagy and apoptosis by sorafenib are
dose-dependent.
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Figure 1.5. Inhibiting non-lethal autophagy by miRs to overcome drug resistance in cisplatin-treated cells. miR200b, miR-24-3p, and miR-199a-5p respectively inhibit atg12, atg4, and atg7 in different stages of autophagy.
The role of METTL3 in autophagy induction in sorafenib resistance cells. By depletion of this RNA, it is possible
to overcome drug resistance in NSCLC cells.
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Long non-coding RNAs (lncRNA) LUCAT1 contributes to cisplatin resistance by regulating the
miR-514a-3p/ULK1 axis in human non-small cell lung cancer [76]. LUCAT1 was upregulated in
cisplatin-resistant cancer cells. ULK1 was determined to be the target gene of miR-514a-3p.
LUCAT1 positively regulated ULK1 expression by targeting miR-514a-3p. Gene ontology
analysis of lung cancer cells revealed that autophagy plays a protective role against cisplatin [99].
That study showed that autophagy is more active in cisplatin-resistant small cell lung cancer cells,
that autophagy protects cisplatin-resistant small cell lung cancer cells, and that anti-malaria drugs,
which increase the pH of lysosomes, enhance cisplatin effectiveness. miR-17 binds ATG7 mRNA
and negatively regulates ATG7 expression [100]. High expression of ATG7 leads to chemotherapy
resistance [101]. Temozolomide, a brain cancer treatment, showed the most resistance in T98G cells
of glioblastoma cell line [102]. Inhibition of miR-17 combined with temozolomide decreases the
drug resistance in T98G cells via autophagic pathway underlying ATG7 regulation [103].
In human lung adenocarcinoma cells, miR-24-3p was found to regulate cisplatin resistance in
small-cell lung cancer by targeting ATG4 and finally, miR-200b participated in autophagy
regulation through ATG12 signaling [97,104]. (Figure 1.5) MiR-133a also plays a prominent role in
tumorigenesis, progression, autophagy, and drug-resistance in various malignancies [105]. It could
incorporate with DOX and cisplatin to improve the drug efficiency in breast cancer cell line MCF7 and Hep-2v cells, respectively [106,107]. miR-133a-3p can promote proliferation and autophagy
in gastric cancer cell lines by binding the 3’-UTR of forkhead protein 3 (FOXP3) [108].
Bortezomib and Carfilzomib. Bortezomib and carfilzomib – two drugs that are used for the
treatment of multiple myeloma (MM) – activate AMPK which promotes prosurvival autophagy
[74]. (Figure 1.6) Similarly, Zhang and colleagues showed that bortezomib suppressed
myristoylated alanine-rich C kinase substrate (MARCKS) causing p53 upregulation, which

released the autophagy initiating Beclin1/Vps34 complex from BCL-2 family proteins [109]. They
also showed that the interaction between Beclin1 and Bcl-xl is weakened in MARCKS-silenced
cells. The reduced Beclin1/Bcl-xL interaction suggest a mechanism whereby MARCKS
suppression induces autophagy [99]. Combining the drugs mentioned above, bortezomib and
carfilzomib, with MARCKS knocked-down cells, led to increased MARCKS suppression.
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Figure 1.6. Role of bortezomib and carfilzomib in autophagic pathway. These drugs trigger autophagy by activating
AMPK pathway and increasing nuclear p53 via MARCKS suppression.
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Therefore, the triggering of lethal autophagy with MARCKs suppression seems to help to combat
drug resistance in the MM cells [99]. (Figure 1.6)
Further studies on HCC have shown the regulation of autophagy by lncRNAs. In response to drugresistance to DOX and sorafenib, LINC00160 (long intergenic non-coding RNA 00160) triggers
autophagy by targeting PIK3 and ATG5 [110]. LINC00160 correlates with breast cancer survival
and regulates the expression of PIK3R3, whose main function is ATG5 activation at the
transcriptional level, and by binding to miR-132 inhibits cell viability and drug resistance in HCC
cells [109]. (Figure 1.7) LINC600 Silencing suppresses non-lethal autophagy and cell proliferation
by decreasing PIK3R3 and miR-132 promotion [111]. In terms of the key autophagy regulator,
ATG7, lncRNA BLACAT is up-regulated in DDP-resistant non-small cell lung cancer (NSCLC)
cells and acts as ceRNA in reducing miR-17 expression. This leads to increased expression of
ATG7 and autophagy promotion [112]. LncRNA XIST also causes autophagy and drug resistance
to chemotherapy by regulating ATG7 expression through miR-17 [113].
However, lncRNAs have different effects on liver cancer cells and are highly upregulated in HCC
tissues and human HCC cell lines including HepG2, Hep3B, PLC, Huh7, and smmc7721 [111,114].
In a similar study on HCC and sorafenib, Lin and colleagues have represented autophagy
suppression by an RNA complex. METTL3 is an RNA methyltransferase complex that inhibits
autophagy under hypoxia environment through PI3k/AKT signaling pathway. METTL3knockdown provides another solution to improve sorafenib drug-resistant in NSCLC via
upregulation of LC3-II, ATG5, Beclin 1 and Vps34 and downregulation of BCL-2 [115,116]. (Figure
1.8)
Gemcitabine and Asparaginase. Gemcitabine is used to treat prostate cancers. Zhang and
colleagues demonstrated that gemcitabine treatment in hormone-independent prostate cancer
(HIPC) has a dose-dependent outcome on the protein level of high mobility group box 1 (HMGB1)

[117]. HMGB1 upregulates of Beclin1/2 complex by dissolving it from Bcl-2 to initiate and regulate
autophagy in the cytosol. Nuclear localization of HMGB1 activates heat shock protein β-1
(HSPB1) expression and autophagy. HMGB1-Overexpression or -knockdown affects HSPB1
level but did not have any effect on Beclin1 level. This leads to the postulate that gemcitabine
sensitivity is due to HSPB1-initiated autophagy. Although the exact pathway of Beclin1 autophagy
induction is still unclear [92]. (Figure 1.9).
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Figure 1.7. LINC00160 upregulates PIK3R3 while miR-132 is downregulated. Silencing of LINC160 suppresses
autophagy by decreasing PIK3R3 and miR-132 promotion in Dox and sorafenib-resistance cells to overcome drug
resistance.
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Figure 1.8. The role of METTL3 in autophagy induction in sorafenib resistance cells. Depletion of METTL3 in
hypoxia conditions activates the autophagic pathway in HCC cells.
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Figure 1.9. Role of gemcitabine in autophagic pathway. HMGB1 regulate non-lethal autophagy in the cytosol.
Nuclear localization of HMGB1 expresses HSPB1 and induce autophagy.
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Asparaginase is a common drug in the treatment of nature kill / T-cell lymphoma. As the name
suggests, asparaginase kills these target cells by depriving them of L-asparagine [118]. Patients with
higher levels of the non-messenger RNA factor BCYRN1 had markedly lower progression-free
survival than patients with lower levels [119]. The authors found that asparaginase increased
degradation of p53 through ubiquitination. This resulted in the increase of autophagy via the
PI3K/AKT/mTOR and p53/mTOR pathways ultimately leading to asparaginase resistance. In this
case, drug resistance was reversed by drug-induced autophagy inhibition in a xenograph model.
Trim14, a protein that has been expressed in gastric cancer (GC) cells, has promoted autophagy
and increased the proliferation of chemotherapy resistance. The autophagic pathway that has been
involved here is consist of PI3K/mTOR/AMPK complex. As it was mentioned before, the
activation of AMPK reversibly regulates the activation of mTOR [78].
In advanced stages of GC, human fibroblast growth factor receptor (FGFR) protein inhibition has
been reported to activate autophagy and improve therapeutic strategies [110]. FGFR activates
mitogen-activated protein kinase (MAPK), and PI3K/AKT complex [120,121]. Peng et al. have
shown that the FGFR inhibitor is connected with autophagy by targeting the AMPK/mTOR
signaling pathway in GC cells [110]. Previous studies have shown the role of TGF-β-activated
kinase 1 (TAK1) in autophagy induction via AMPK/mTOR signaling pathway [81,122,123]. In sum,
with the combination of EFGR and TAK1 inhibitors, chemotherapy resistance could potentially
be overcome [94].

Cancer stem cells and autophagy
Cancer is in large part a stem cell disease. Recently, mechanistic links among cancer stem cell
factors and autophagy have been uncovered. In the context of our discussion of GC and colorectal
cancer, it was recently determined that Beclin-1 is partially responsible for chemoresistance,
stemness, and the epithelial-mesenchymal transition [124]. In that work, the sex-determining region
Y-box2 (SOX2), a master regulator of embryonic and induced pluripotent stem cells, increases the
expression of Beclin-1. This increases autophagy and activated a malignant phenotype.
Furthermore, xenograph mouse models showed that SOX2 inhibition reduced autophagy and
abated tumor growth and decreased chemotherapy resistance in vivo. These results confirm those
of a previous study suggesting that SOX2 plays a crucial role in maintaining GC stem cell
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properties [125]. Certainly, more links between stemness and autophagy will be uncovered that will
hopefully be able to be exploited as drug targets.

Targeting autophagy to overcome drug resistance
Combining chemotherapy drugs with autophagy inhibitors can optimize the drug concentration,
accelerate binding with the targets and/or transporters, and inhibit autophagy leading to cell
apoptosis and eventually more efficient anticancer treatment. Table 1.2 provides a list of
complement enhancers to improve the drug resistance in cancer. Ramirez and colleagues saw an
increase in ATGs, SQSTM1, Beclin-1, and ULK1 after 5-fluorouracil (5-FU) treatment of human
colon cancer cell line HCT-116 in vitro [126]. But when they added chloroquine (CQ), an autophagy
suppressor, LC3-II and SQSTM1 levels increased indicating that autophagy was blocked at
autophagosome formation. It should always be noted that autophagy is a dynamic process and can
be halted at certain gateway points [3]. Incomplete autophagy and autophagosomes accumulation
can cause oxidative stress and lead to organelles dysfunction and, ultimately, cell death [79,127].
Indeed, adding CQ to 5-FU increases cell apoptosis [126].
In the following, more examples of multidrug resistance and autophagy are discussed. In some
recent studies on cancer treatment by dihydroartemisinin (DHA), apoptosis has been noticed
widely in autophagy induction and tumor cells. For example, in breast cancer, a combination of
DHA and epirubicin, another breast cancer drug, improved the treatment due to higher drug
concentration and prolonged drug interference to the cells through the mTOR autophagic signaling
pathway [79,128].
DHA interacts with Bcl-2, therefore it blocks Beclin1/Bcl-2 complex. Beclin1 activates PI3K
complex to promote autophagy. On the other hand, DHA suppresses binding Bcl-2 with Bax,
resulting Bax association with the mitochondria, to activate apoptosis cascade via the mitochondria

pathway. Epirubicin intercalates DNA strands, resulting in apoptosis of cancer cells. Moreover,
DHA enhances the uptake of epirubicin due to the distribution of the cell membrane to DHA [80].
Similarly, in colon cancer, DHA+DOX enhanced the localization of DOX in the nucleus, followed
by autophagy enhancement and, finally, cancer cell apoptosis [110]. Other than Bax, DHA
contributes with other cell mechanisms, such as inhibition of NF-κB, generation of active oxygen
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Table 1.2: The effect of drug enhancer co-treatment with chemotherapy on autophagy. MARCKS: myristoylated
alanine-rich C kinase substrate; LINC00160 :long intergenic non-coding RNA 00160; METTL3: methyltransferase
like 3; HMGB1: High mobility group box 1; TTCC: T-type calcium channel; TRAIL: Tumor necrosis factor-related
apoptosis-inducing ligand; MM: multiple myeloma; HCC: hepatocellular carcinoma cancer; VPS: vacuolar protein
sorting; Akt: A serine/threonine kinase; PTEN: phosphatase and tensin homolog; NF-κB: nuclear factor of kappa light
polypeptide gene enhancer in B-cells; PI3K: phosphoinositide 3-kinase; HSPB1: Heat shock protein β-1; SQSTM1:
sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1; AMPK: adenosine monophosphate-acticated
kinase; BCL-2: B-cell lymphoma 2; Caspases: cysteine-dependent aspartate-directed proteases
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radicals, autophagy regulation, and apoptosis induction [129–131]. Downregulation of NF-κB
promotes ROS and suppresses mTOR signaling leads to autophagy induction [132]. In an in vivo
study on rat ventricular cardiomyocytes, DOX-induced autophagy was proven through GATA4
pathway. In response to DOX treatment, GATA4 protein is depleted, which results in Bcl2
inhibition and ATG5, ATG7, ATG12, and Beclin 1 upregulation. (Figure 1.10) Ultimately, it leads
to autophagy activation that contributes to cardiomyocyte death [133]. The drug combination also
resulted in downregulation of Bcl-xl [132]. Recent strategies for overcoming autophagy-based
resistance to DOX include the co-delivery of DOX with mirror siRNA that knocked down ATG7
[134]. Another study has shown that alteration of paclitaxel (PTX) with CQ caused autophagy
inhibition in lung adenocarcinoma cells and ovarian carcinoma cells [106].
In a different approach to breast cancer, Liu and colleagues precisely demonstrated the notable
result on Trastuzumab emtansine (T-DM1) autophagy induction in a type of breast cancer cells
[134]. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients who have
progressed after prior treating with trastuzumab and taxane received T-DM1, an antibody-drug
conjugate (ADC) of trastuzumab [82]. T-DM1 has trigger autophagy inhibition and cell apoptosis
through the Caspase-3/7 activation pathway and shows therapeutic improvement. They also
revealed a molecular pathway of T-DM1, which first T-DM1 reduces p-mTOR-S2448 expression
in cells. Then, mTOR and Akt regulators are dephosphorylated and trigger autophagy [116].
Hormone therapy has also reported for HCC treatment underlying autophagy [137]. Thyroid
hormone is involved PTEN-induced kinase1 pathway and triggers selective mitophagy, autophagy
of mitochondria [138]. Therefore, it can be an option for liver cancer treatment while further
investigations are required.
Another chemotherapy-resistant disease is malignant Melanoma that is affected by autophagy
activation. Vemurafenib tends to reduce the standard type of this tumor, and melanomas harbor
BRAF gene mutation kinase inhibitors. However, these tumors repeatedly face drug resistance
through chronic Vemurafenib-induced autophagy [83]. It has been observed in a study on mutant
melanoma cells that it is possible to overcome the resistance development by blocking autophagy.
Barcelo et al. have proposed an autophagy blocker complex to treat melanomas. This complex
consists of a biomarker, T-type calcium channel (TTCC), and BRAF inhibitor. The results have
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Figure 1.10. Role of DHA and DOX in autophagic pathway. Combination of these drugs enhances autophagy by
downregulation of Bcl-xl.
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shown a successful progression in post-therapeutic levels with mibefradil, the chemicals to block
TTCCs [138].
Oleanolic acid, a chemical found in food and plants, is used in the treatment of leukemia, breast,
lung, and liver cancer [139]. Oleanolic acid can inhibit the phosphorylation of PI3K in leukemia
cells through the Akt/PI3K/mTOR signaling pathway and ROS pathway, or it dephosphorylates
mTOR in prostate cancer cells [140–142]. Zhou et al. also revealed the autophagy inhibition role of
Oleanolic acid in HCC cells. Their results confirm that Oleanolic acid has induced autophagy
through the Akt/mTOR pathway by downregulating the Beclin2/Beclin1 ratio followed by
mitochondrial dysfunction and eventually cell apoptosis [143].
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) enhances cancer cell apoptosis
via binding with death receptors and caspase cascade activation. Cancer cells are often resistant to
TRAIL due to their insufficient expression of death receptors (DR4/DR5), excessive expression
of decoy receptors, or genetic and epigenetic modification of TRAIL receptors [136,144]. In an in
vitro study of lung A549 cells, it has shown that small doses of sertraline in combination with
TRAIL notably enhances apoptosis [81]. Sertraline is an antidepressant drug that has proved antitumor activities against cancers [145]. Sertraline mediates apoptosis through the inhibition of
autophagy via the downregulation of AMPK phosphorylation and activation of DR5 in TRAILresistant lung A549 cells. Besides, sertraline was demonstrated to decrease the expression of BCL2 and increase caspase-3 activity [146].
As an example of lethal autophagy enhancer, irinotecan (IRI) has an anti-tumor activity for secondline treatment of advanced gastric cancer. IRI promotes MAPK signaling proteins p-JNK and pp38 associated with ROS and induces lethal autophagy [111]. Furthermore, after IRI treatment in
MGC803 and SGC7901 cells, two gastric cancer cell lines, it has been observed that ROS
generation promotes autophagosome formation by phosphorylating BCL-2 and disrupting the

BCL-2/Beclin 1 complex [147].

Current clinical trials
There are currently nine clinical trials of cancer chemotherapy drugs that have an autophagy
aspect. Eight of the nine chemotherapy treatments group an anti-cancer drug with
hydroxychloroquine. Thus, the approach is to block autophagy by inhibiting the merger of the
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autophagosome with the lysosome. This will lead to the accumulation of autophagosomes in any
cell that takes up hydroxychloroquine. It will be interesting to see how these combination therapies
affect the normal autophagic process in healthy cells which is so crucial to organism-wide
homeostasis.
Conclusions
Treating malignant cells with chemotherapy drugs can result in the increase in ROS generation,
which leads to autophagy and cancer cell survival. This is one of many defenses cancer cells trigger
to maintain viability and to proliferate. Combination therapies that utilize cytotoxic anti-cancer
drugs along with autophagy inhibitors may increase positive outcomes for patients. But as always,
targeting mostly cancer cells and avoiding healthy tissues is a major obstacle. Off-target autophagy
inhibition could trigger several side effects including increased susceptibility to infection,
increased fatty acid accumulation, and cellular senescence. Recently, immunotherapy such as
check point strategies have shown success in the clinic. PD-1 is a prominent target in these
strategies. Reduction of PD-1 increases autophagy. Therefore, check point therapies may also
benefit from co-administration of autophagy-reducing agents.
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CHAPTER 2
SOFT, POLY-ETHYLENE-GLYCOL-BASED (PEG-BASED) NANOPARTICLES (NPS)
REDUCE AUTOPHAGOSOME SIGNAL, ROS, AND DO NOT ACIDIFY PHAGOLYSOSOMES IN MACROPHAGES
Introduction
Soft poly-ethylene-glycol (PEG) nanoparticles (NPs) that are intravenously administered to
mammals localize mostly to macrophages in the liver. Paradoxically, liver macrophages are also
intriguing targets for NPs because they are at the hub of immunity and metabolism, two prominent
drivers of mammalian health, which are intertwined with autophagy [148,149,150]. Therefore,
understanding how macrophages process NPs is of keen interest to the field of nanomedicine. Yet
it is unclear how macrophages respond to NPs. It is widely assumed that macrophages “clear” NPs
because they are foreign objects. This could occur via the deposition, or opsonization, of foreignbody indicators on the NP, such as complement and immunoglobulin [151,152].
Fc and complement receptors on the surfaces of immune response cells such as macrophages and
neutrophils would recognize these opsonized factors, bind them, and internalize the NP via
phagocytosis where it would ultimately be enzymatically degraded in the lysosome. If so, these
factors should increase in number. One of the most crucial is the transcription factor EB (Tfeb),
which is a master regulator of lysosome biogenesis and expression of autophagic genes [153–155].
Thus, Tfeb levels would be expected to increase if any object is being trafficked to the lysosome
for degradation. This would include pathogens and possibly NPs. An additional part of this story
is that pathogens have evolved to escape the endo-phagosome [156]. Autophagy is triggered to
capture these cytosolic pathogens, engulf them, and deliver them to lysosomes. Since NPs that
carry nucleic acids are now designed to escape endo-phagosomes, for example pfizer sars-cov-2
mrna vaccine, the autophagy pathway becomes crucial to understand in the context of soft NPs.
Though the hypothesis of serum proteins depositing on NPs leading to clearance by phagocytes is
widely accepted, open questions remain. Indeed, the most prominent corona factors on LNPs are
not immunoglobulins or complement but apolipoproteins ApoA-I, ApoB-100, ApoC-III, and
ApoE [157,158]. These apolipoproteins are structural components of chylomicrons, HDL, LDL, and
VLDL. It is possible that apolipoproteins that bind NPs take the NP to the
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apolipoprotein/lipoprotein receptor on the cell surface. Since macrophages have high numbers of
lipoprotein receptors [159], NPs could be guided to these cells through this mechanism. Yet, it is
unclear how the NP would enter the cell if it binds lipoprotein receptors on the cell surface. hHDL
particles are postulated to remain bound to the macrophage surface whereas hLDL particles are
postulated to be endocytosed and processed in the lysosome. Unfortunately, the binding affinity
and rate constants of apolipoproteins for LNPs are largely unknown.
Recently, an additional NP uptake mechanism emerged. PEG was found in the cholesterol binding
pocket of endosomal LIMP-2 [160]. LIMP-2 is in the CD36 superfamily of proteins along with the
major high-density lipoprotein receptor, SR-BI. These proteins function as lipoprotein receptors
and cholesterol and fatty acid transporters. PEG NP micelles bind SR-BI and are internalized, at
least partially, by macrophage SR-BI [161]. It is unclear which additional proteins may or may not
assist in the NP internalization mechanism. Thus, PEG itself can bind receptors of lipoproteins. It
is currently unclear which of these pathways result in NP uptake by macrophages. It could certainly
be a combination of these pathways.
It is further hypothesized that NPs taken up by macrophages are processed by autophagy [162,163].
This phenomenon is mostly seen with hard NPs that have high aspect ratios [156]. If the NP stays
in the endo-phago-lysosome pathway, it is unclear why autophagy would be needed. But if NPs
localize to and are processed by lysosomes, Tfeb should increase. Tfeb increase should lead to
autophagy as mentioned above. This could be the link between NPs that do not escape endophagosomes and their triggering of autophagy. Again, NPs that are designed to escape endophagosomes will most likely trigger a different form of autophagy.
Cells use autophagy to regulate a variety of processes including response to pathogens. The
signature autophagic event is the formation of a double membraned autophagosome [164]. The
autophagosome engulfs areas of the cytosol in macroautophagy or specific targets like invading
pathogens in xenophagy [156]. Autophagosomes merge with the lysosome and the contents of the
former are degraded. Many pathogens trigger selective autophagy through p62/SQSTM1, which
binds the pathogen and delivers it to a forming autophagosome, the phagophore [165]. The
components of pathogens such as the gram-negative endotoxin, LPS, also contribute to autophagy
initiation. The binding of LPS, to toll-like receptor 4 (Tlr4) results in Traf6 both ubiquitinating
Becn1 and activating Ulk1 [166,167]. Both actions trigger autophagy [168]. LPS-induced autophagy
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is Mapk/p38 and Ticam1/Trif dependent but does not involve the Tlr4 binding partner MyD88
[169]. MyD88 is a widely studied factor that is downstream if Tlr4. Other connections between
TLRs and autophagy include the recruitment of Atg16l1 to the plasma membrane at the site of
pathogen entry [170,171]. LPS induces interleukin-1 expression through ROS generation [172]. Tnf
and Il1α induce autophagy as do IFNγ, IFNα, and IL6.
In the context of NPs, most is known about autophagy triggered by hard NPs such as silica, carbon
nanotubes, gold and silver metals, and fibers [173]. We point the reader to a recent review of NPinduced autophagy [174]. Semi-soft cross-linked polystyrene (PS) nanoparticles particles activate
Tfeb [153]. Open questions remain about the autophagic response to soft PEG NPs. It is unclear if
soft PEG NPs trigger selective autophagy, canonical autophagy, or if they increase autophagy at
all [175,176]. We aim to answer this question. Further, if the macrophage response to PEG NPs is
similar to the response to pathogens and LPS, one would expect innate immunity to play a role in
PEG NP processing. Yet, PEG-phosphatidylserine liposomes reduced LPS-elevated Tnfα mRNA
levels in RAW 264.7 macrophages [177]. This result is interesting because there could be parallels
between the uptake of soft NPs of certain chemistries – like phosphatidylserine – and efferocytosis,
which is a natural macrophage process of clearing apoptotic cells. Efferocytosis appears to help
macrophages remain viable [178]. We explore the concept of NPs increasing macrophage
proliferation below.
Our goal was to understand how sustained incubation of soft PEG-based NPs with macrophages
over 24-hours affected how the NPs entered macrophages, how macrophages processed the NPs
once they were taken up. To achieve these goals, we incubated IFNγ-polarized RAW264.7 murine
macrophages (here after, macrophages) with human high-density lipoprotein (hHDL), human lowdensity lipoprotein (hLDL), group A streptococcus pathogens (JRS4 cells), LPS, PEG (MW 6000),
PEG-based cylindrical micelles (CNPs), PEG-based spherical micelles (SNPs), and PEGylated
lipid nanoparticles (LNPs). hHDL and hLDL were used as controls to test similarities in
macrophage response among lipoproteins and soft PEG-NPs. JRS4 cells were used as a positive
control for a phagocytosis-, inflammatory-, and autophagy-triggering pathogen. LPS was used as
a positive control for autophagy and inflammation. We incubated macrophages with hHDL, hLDL,
JRS4 cells, LPS, PEG (MW 6000), PEG-PBD cylindrical micelle NPs (CNPs), and PEG-PBD
spherical micelle NPs (SNPs) macrophages and determined the extent of autophagosome
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formation, lysosome formation and function, ROS production, cell proliferation, and cytokine
secretion. We chose 24 hours as our analysis timepoint for all reagents, except JRS4 cells (3 hours
[156]), because most PEG NPs that are administered to mice have a t1/2 of ~24 hours post injection.

Results
We wished to determine the effects of PEG-based cylindrical micelle NPs (CNPs), PEG-based
spherical micelle NPs (SNPs), and PEGylated lipid vesicle NPs (LNPs) on M1-polarized
RAW264.7 murine macrophages (hereafter, macrophages) over 24-hours of continual interaction
in vitro. These are the timescales over which macrophages in a mouse are exposed to circulating
NPs post tail-vein injection. The CNPs and SNPs used in this study had a PEG exterior and a
polybutadiene (PBD) interior (Fig. 2.1A). The LNPs used in this study were a 56:38:5 molar ratio
of

hydrogenated

soy

phosphatidylcholine

(HSPC),

cholesterol

and

N-(carbonyl-

methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt
(MPEG-DSPE) (Fig. 2.1B). These lipids form the bilayer vesicle of the anti-cancer drug DOXIL.
Schematic diagrams of CNPs, SNPs, and LNPs are shown in Fig. 2.1C. All three NPs are stable in
PBS and in standard macrophage cell culture media: DMEM + 10% FBS (Fig. 2.1D).
We used group A streptococcus pathogens (JRS4 cells) as a positive control for phagocytosis,
selective autophagy, and inflammation [156]. A significant fraction of macrophages took up JRS4
cells stained with the DNA dye TOTOTM-3 iodide 642/660 after 3 hours of incubation (Fig. 2.1E).
We chose this shorter time because we did not want the cells to undergo apoptosis. We used human
HDL (hHDL) and human LDL (hLDL) as positive controls for macrophage lipoprotein uptake.
We used LPS as a positive control for an inflammatory response.
Macrophages took up hHDL, hLDL, CNPs, SNPs, and LNPs that were each carrying the same
near-infrared (NIR) fluorescent dye over 24 hours incubations (Fig. 2.2A). We used flow
cytometry to determine the quantity of hHDL, hLDL, CNPs, SNPs, and LNPs in the supernatant
during the incubation with the macrophages. Our goal was to have enough of these reagents in the
cell culture media over the duration of the 24 hours so that the cells could continually take them
up. In each incubation, there was signal for the lipoprotein and NPs at the 24-hour time point (Fig.
2.2B-F). Note that CNPs had the most persistent presence in the cell culture media over the 24hours (Fig. 2.2G).
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Figure 2.1. Properties of the nanoparticles (NPs) used in this study. (A) Chemistries of the components of the
CNP and SNP micelles. For the CNPs: i = 46, j = 56. For the SNPs: i = 69, j = 132. (B) An LNP is comprised of
HSPC/CHOL/PEG2000-DSPE (56.2 : 38.5 : 5.3 mol:mol). For the LNPs: k = 8 and l = 8, m = 8 and n = 8, and o =
45. (C) Schematic drawings of the three NPs used in this study. Drawings are simplified: a one-micron-long CNP
has ~1M copolymers, a 50 nm SNP has ~30k copolymers, and a 100 nm LNP has ~85k lipids. (D) Electron
micrographs of the CNPs, SNPs, and LNP used in this study. CNPs, SNPs, and LNP were incubated in PBS (top
panels) or in DMEM + 10% FBS media that had been incubated with macrophages for 3 hours (bottom panels).
Scale bars are 500 nm. (E) Fluorescence microscopy images of M1-polarized RAW264.7 murine macrophages
after 3h incubations with JRS4 cells carrying a red DNA dye (TOTO). Scale bar is 50 microns.

31

Figure 2.2. Internalization of the particles in macrophages. (A) Fluorescence microscopy images of IFNγpolarized RAW264.7 murine macrophages after 24h incubations with the indicated lipoproteins and NPs carrying
near-infrared (NIR) dye. Scale bars are 50 microns. (B-F) Plots of the forward scatter and fluorescence intensity
(NIR channel) of the cell culture media over the time course of lipoprotein and NP incubation with macrophages.
The data points represent lipoprotein and NPs that were not taken up by macrophages. A maximum of 100 ml of
cell culture media was analyzed for each flow cytometry experiment.
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hHDL, hLDL, CNPs, SNPs, and LNPs lower autophagosome levels in murine macrophages
It is widely held that NPs trigger autophagy in mammalian cells post internalization. To further
explore the effects of LNPs on macrophage autophagy, we used fluorescence microscopy and flow
cytometry analysis to measure autophagosome levels. We started with hHDL, hLDL, and JRS4
cells as controls. We incubated hHDL carrying NIR dye with macrophages for 24 hours, washed
the cells with PBS, and stained them with an autophagosome dye (CYTO-ID). The autophagosome
signal dropped 60% compared to PBS controls as measured by flow cytometry of CYTO-ID (Fig.
2.3A-C). We then used starvation (DMEM without 10% FBS), the mTOR inhibitor rapamycin
(RAPA 250 nM), and LPS (250 ng/ml) to trigger autophagy. Starvation inhibits mTOR, which in
turn activates autophagy. Amino acid deprivation - which can be caused by pathogens - is the
strongest trigger of starvation-induced autophagy [179]. Rapamycin forms a complex with FK506binding protein (FKBP12), which blocks mTOC1’s kinase activity [180]. Since active mTOR
inhibits autophagy, rapamycin triggers autophagy by this effect. LPS triggers autophagy that
defends the cell against invading pathogens. Each of these challenges caused the CYTO-ID signal
to increase (Fig. 2.3A-C).
To determine the effects of HDL on these challenges we performed co-incubation experiments of
each of the above challenges with hHDL. hHDL lowered the CYTO-ID signal that was raised by
each challenge. This shows that HDL has either anti-autophagosome formation properties or
increases the flux of the autophagosome-lysosome merger. The second possibility is unlikely since
hHDL did not increase the expression of the lysosome biogenesis factor Tfeb (Q-value = 0.98 >
0.05), although it was significantly increased by hLDL (+20.6; Q-value = 4e-5), which agrees with
the finding that LDL is processed through lysosomes [181]. We performed the same CYTO-IDlabeled autophagosome experiments with hLDL in place of hHDL and observed similar reductions
in CYTO-ID signals. However, hLDL was not as effective at lowering CYTO-ID signal versus
hHDL (Fig. 2.3D-F). We used JRS4 cells as a positive control for selective autophagy. Indeed,
three-hour incubations of JRS4 cells labeled with the TOTO DNA dye increased the CYTO-ID
signal in macrophages by 60% (Fig. 2.4A-B).
To determine the effects of our NPs on autophagosome abundance, we separately incubated PEG,
CNPs, SNPs, and LNPs with macrophages for 24 hours in four different culture conditions: 1)
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Figure 2.3. hHDL and hLDL reduce autophagosome signals in macrophages. (A) Fluorescence micrographs

of macrophages that have been incubated with the indicated reagents for 24 hours subsequently stained with
CYTO-ID to visualize autophagosomes. (B) Plot of the intensity of the hHDL (NIR) signal of the cells depicted
in (A) measured by flow cytometry. (C) Plot of the intensity of the autophagosome signal of the cells depicted in
(A) measured by flow cytometry. (D) Fluorescence micrographs of macrophages that have been incubated with
the indicated reagents for 24 hours. (E) Plot of the intensity of the hHDL (NIR) signal of the cells depicted in (D)
measured by flow cytometry. (F) Plot of the intensity of the autophagosome signal of the cells depicted in (D)
measured by flow cytometry. N = 5000 x 3 (triplicate) for flow cytometry data. p-values were calculated using
Microsoft Excel’s t.test() function. Scale bars are 10 microns.
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Figure 2.4. JRS4 increases autophagosome signals in macrophages. (A) Fluorescence micrographs of
macrophages that have been incubated with the JRS4 for 3 hours subsequently stained with CYTO-ID to visualize
autophagosomes. (B) Plots of the fluorescence intensity of the macrophages shown in (A) measured by
flow cytometry. N = 5000 x 3 (triplicate) for flow cytometry data. p-values were calculated using Microsoft
Excel’s t.test() function. Scale bars are 10 microns.
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normal (DMEM + 10% FBS), 2) starve (DMEM), 3) RAPA (250 nM rapamycin + DMEM + 10%
FBS), and 4) LPS (250 ng/ml LPS + DMEM + 10% FBS). We washed the cells in PBS and
identified NPs by NIR dye. We identified autophagosomes with CYTO-ID using fluorescence
microscopy and flow cytometry as in the experiments involving hHDL, hLDL, and JRS4 cells.
Macrophage NIR signal (a measure of NIR uptake) followed an increasing trend from CNP < SNP
< LNP (Fig. 2.5A-H). CNPs have the highest entropic energy because they are polymers; therefore,
entropy is maximized when they are diffusing in the media above the macrophages. SNPs should
not have a large entropic component in the bulk; therefore, the energetic cost of binding
macrophages should be minimal. It has recently been shown that both CNPs and SNPs interact
with SR-BI and LIMP-2 [161]. The LNP entry mechanism is postulated to be heavily influenced by
its protein corona, which has components of lipoproteins [157,158]. However, note that LNP signal
in macrophages is highest in starvation conditions where the protein corona should come only
from proteins excreted by the macrophages. Therefore, it is puzzling why macrophages should
take up LNPs in such high quantities in starvation (DMEM only) conditions.
In DMEM + 10% FBS conditions, PEG had little effect on autophagosome signal; CNPs, SNPs,
and LNPs all reduced autophagosome signal by ~25% (Fig. 2.5A,I). In starved conditions, PEG,
CNPs, SNPs, and LNPs reduced autophagosome signals by 30%, 30%, 50%, and 40% (Fig.
2.5B,J). PEG increased the macrophage autophagosome signal by 30% when co-incubated with
rapamycin; CNPs, SNPs, and LNP reduced the autophagosome signal by 20%, 52%, and 50%
(Fig. 2.5C,K). For LPS co-incubation, the changes were PEG (0%), CNPs (45%), SNPs (46%),
and LNP (40%) (Fig. 2.5D,L). P-value less than 0.05 (equal to zero in most cases) means the data
of those experiments is statistically significant. These results show that CNP, SNP, and LNP but
not PEG itself, lower autophagosome levels as measured by CYTO-ID.
To further determine if our PEG and PEG NP reagents affected the autophagic process, we
compared the number of macrophages before and 24 hours after PEG, CNP, SNP, and LNP
addition with chloroquine (CQ) as a control for blocking autophagosome-lysosome fusion and
halting cell division [182]. None of our reagents hampered macrophage division, whereas
chloroquine stopped cell growth (Fig. 2.6A,B). This shows, in part, that PEG and PEG NPs do not
block autophagosome-to-lysosome fusion. It also shows that PEG and PEG NPs do not interfere
with cell division or cause proliferation-hampering toxicity in macrophages in vitro. This agrees
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with studies showing that PEG-based NPs promotes mouse primary macrophages survival in vitro
[183]. It also shows differences in cellular proliferation/apoptosis response to NPs that have
different chemistries and densities [184].

Figure 2.5. CNPs, SNPs, and LNP lower autophagosome signal, whereas PEG itself has little effect. (A-D)
Fluorescence micrographs of macrophages that have been incubated with the indicated reagents for 24 hours and
subsequently stained with CYTO-ID to visualized autophagosomes. Scale bars are 10 microns. (E-H) Plots of the
intensity of the NIR signal of the macrophages depicted in (A-D) measured by flow cytometry. (I-L) Plots of the
intensity of the autophagosome signal of the cells depicted in (A-D) measured by flow cytometry. N = 5000 x 3
(triplicate) for flow cytometry data in (E-L). p-values were calculated using Microsoft Excel’s t.test() function.
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Figure 2.6. PEG, CNPs, SNPs, and LNP did not hamper macrophage division. (A) Phase contrast
micrographs of macrophages before and after being incubated with the indicated reagents for 24 hours. (B) Plot
of the normalized number of macrophages depicted in (A). The number of macrophages in four separate quadrants
of 0.86 mm2 were averaged to obtain the numbers in (B). Scale bars in (A) are 50 microns.
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hHDL, hLDL, PEG, CNPs, SNPs, and LNP lower ROS levels but do not consistently resolve
ROS levels that are increased by starvation, rapamycin, and LPS
ROS production is used by phagocytes to directly damage pathogens [185] and also to induce
autophagy to engulf the pathogen in an autophagosome [186]. ROS generation is also triggered by
the uptake of many hard NPs such as nanotubes [173]. Less is known about the effects of soft NPs
on ROS generation. To determine the effects of our lipoproteins and NPs on ROS production, we
incubated hHDL, hLDL, PEG, CNPs, SNPs, and LNP with our macrophages for 24 hours and
subsequently stained the cells with a proprietary ROS dye. Each of these additions caused a
decrease in ROS dye signal with SNPs having the strongest effect (Fig. 2.7A,B). We repeated these
experiments and either starved, added rapamycin, or added LPS to the macrophages at the
beginning of these 24-hour co-incubations. Only hLDL and SNPs lowered the ROS signal in
starved macrophages. None of the other lipoproteins or NPs had a reducing effect on ROS signal
in the starvation, rapamycin, or LPS experiments. Rapamycin is unique among autophagytriggering reagents (mTOR inhibition) because it has ROS-lowering effects [187]. Activation of
Nox2 leads to the production of ROS. This can occur through LC3-associated phagocytosis (LAP)
[188]. In LAP, Rubicon stabilizes NOX2 to produce ROS.
JRS4 cells increased the macrophage ROS signal by 60% after a 3-hour incubation (Fig. 2.8A,B).
Nox2 levels increased slightly as measured by western blot (Fig. 2.8C,D). We analyzed known
ROS regulator mRNA transcripts in our macrophages [189]. Of the major genes associated with
ROS, the cold shock domain containing E1 protein, Csde1, increased to varying degrees across all
five reagent additions (not shown). Csde1 knockdowns increase ROS levels [190]. Thus, higher
Csde1 values should inhibit ROS. LPS treatment increased Nos2 and Prdx5 levels. Nos2 interacts
with p62/Sqstm1 in macrophages and is degraded in lysosomes [191]. This is a mechanism by which
autophagy controls nitrous oxide production during inflammation. JRS4 cells increased Stat6 and
hLDL increased Xdh levels. LNPs had no effect on these transcript levels. The STRING database
shows no connectivity of Csde1, Nos2, or Xdh. However, Prdx2 interacts strongly with Cybb,
Cyba, Ncf1, Noxo1, and Rac2.
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Figure 2.7. hHDL, hLDL, PEG, CNP, SNP, and LNP reduce ROS levels but cannot restore basal ROS
levels after rapamycin or LPS challenge. (A) Fluorescence micrographs of macrophages that were incubated

with the indicated reagents (without NIR dye) for 24 hours and then stained with a ROS dye. Scale bars are 10
microns. (B) Plots of the fluorescence intensity of the macrophages shown in (A) measured by flow cytometry.
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Figure 2.8. JRS4 increses basal ROS levels. (A) Phase contrast and fluorescence microscopy images of
macrophages incubated first with JRS4 pathogens for 3 hours then ROS dye. Scale bars are 10 microns. (B) Plots
of the fluorescence intensity of the macrophages shown in (B) measured by flow cytometry. (C) Western blots of
NOX2 after JRS4 addition (3 hours) to macrophages. (D) Plot of the intensities of the bands in (C). p-values were
calculated using Microsoft Excel’s t.test() function. Western blots were run in triplicate.

41

hHDL, CNPs, SNPs, do not increase lysosomal pH in contrast to hLDL, LNPs, starvation,
rapamycin, and LPS
It is unclear if soft PEG-based micelles like CNPs and SNPs or soft PEGylated liposomes like
LNPs enter cells via the endosome-lysosome pathway although it is widely assumed that this is
the entry mechanism. Phagocytosis is a subset of this endo-lysosome pathway. The working
postulate is that most NPs are phagocytosed and then degraded in the lysosome. This excludes NPs
that are designed to escape endosome such as ionizable liposomes [192]. We cultured our
macrophages in DMEM + 10% FBS, DMEM, DMEM + 10% FBS + rapamycin, and DMEM +
10% FBS + LPS. We co-incubated the same macrophages with PBS, PEG, CNPS, SNPs, and
LNPs with macrophages for 24 hours, washed the cells with PBS and stained with Lysotracker.
Lysotracker signal stayed constant across all conditions, with the exception of an increase for PEG
incubation in the LPS condition (Fig. 2.9A-H). This shows that these reagents have minimal effect
on lysosome biogenesis – at the end of 24-hour incubations. To determine if our NPs increased
lysosomal pH, we incubated macrophages with pHrodo dye, which fluoresces when the cellular
pH is below ~6.5. Since phagosomes and lysosomes have low pH values, pHrodo is essentially a
marker of phagocytosis and lysosome activity [193]. We performed 24-hour incubations of PEG,
CNPs, SNPs, LNPs with macrophages. Positive controls for lysosome activation were hLDL (via
LDLR-mediated endocytosis and Niemann-Pick-mediated processing of LDL contents), starvation
(lysosome activation through autophagy), and rapamycin (lysosome activation through
autophagy). The NP negative control for lysosome activation was hHDL, since hHDL does not
seem to enter macrophages via endocytosis although this is somewhat controversial. hLDL and
rapamycin increased pHRodo signal, whereas hHDL and SNPs lowered pHRodo signal (Fig.
2.10A,B). PEG, CNPs, and starvation conditions had little effect on pHRodo signal compared to
PBS. We mined our mRNA data for transcripts involved in cellular uptake, phagocytosis, and
lysosome function. In agreement with our fluorescence microscopy and flow cytometry data, only
JRS4 cells and LPS had impact on factors involved in these pathways (not shown). Interestingly,
hHDL increased Apoe and Trl7 transcripts; hLDL increased Apoe, Rab12, and Tfeb transcripts;
and LNPs increased Sirpα and Tlr3 transcripts (not shown). Tlr7-/- mice are protected from Apoe/-

atherosclerosis, but HDL levels stayed the same in these mice [194]. Thus, it is unclear if HDLs
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enter macrophages through Tlr7. Rab12 may be responsible for transport of endosomes to
lysosomes [195]. Thus, Rab12 may contribute to LDL processing. Endosomal Tlr3 plays a

Figure 2.9. CNPs, SNPs, and LNPs have a minimal effect on lysosome signal. (A-D) Fluorescence
micrographs of macrophages that were incubated with the indicated reagents for 24 hours, then stained with
Lysotracker. (E-H) Plots of Lysotracker intensity of the macrophages in (A-D) as measured by flow cytometry.
Scale bars are 10 microns. N = 5000 x 3 (triplicate) for flow cytometry data.
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Figure 2.10. CNPs, SNPs, and LNPs have a minimal effect on cellular pH. (A) Fluorescence micrographs of
macrophages that were incubated with the indicated reagents for 24 hours, then stained with pHrodo dye. (B) Plot
of the pHrodo intensity of the macrophages in (A) as measured by flow cytometry. Scale bars are 10 microns. N
= 5000 x 3 (triplicate)
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protective role by inhibiting the protein degradation that is triggered by hard TiO2 NPs [196]. These
results suggest that hLDL and LNPs are potentially processed by lysosomes, and that hHDL, PEG,
SNPs, and CNPs are not.

CNPs, SNPs, and LNPs reduce the secretion of cytokines by macrophages
We collected the media from each well of macrophages after 24-hour incubations of CNPs, SNPs,
LNPs, LPS, and PBS and determined the levels of 32 cytokines by ELISA (Eve Technologies).
Cytokine levels were normalized by the number of cells in each culture well. Cytokine levels in
the CNP, SNP, LNP, and LPS experiments were normalized by the levels in the PBS control.
Surprisingly, CNPs, SNPs, and LNPs either reduced or did not increase the abundance of most
cytokines in the media after 24 hours (Fig. 2.11A-AF). Of the three NPs, LNPs had the largest
cytokine reduction effects, including GM-CSF, IL-3, IL-6, IL-12p70, LIF, MCP-1, and VEGF.
LPS greatly increased the secretion of G-CSF, GM-CSF, IL-6, LIF, MCP-1, MIP-2, and
RANTES/CCL5. These results show that PEG NPs are capable of lowering macrophage cytokine
secretion and do not trigger a cytokine secretion reaction that is similar to that triggered by LPS.
JRS4 cells and LPS caused wide-spread increases in pro-inflammatory factor transcripts (not
shown). On the other hand, hHDL, hLDL, and LNPs triggered either no change or reduced change
in log2(FC) values. The notable exception was the increase in Il1rl1 by hLDL. This member of the
Tlr family does not induce an inflammatory response through activation of Nfκb, but does activate
MAP kinases. The reduction of inflammation by hHDL is to be expected [197,198]. Mechanistically,
SCARBI-/- (the gene that codes for SR-BI) mice are hypersensitive to LPS [199]. LPS-induced
cytokine expression in these animals was dependent on Nfκb, JNK, and p38. PEG and PEG-NPs
bind SR-BI [160,161]. Therefore, a potential mechanism for inflammation inhibition by CNPs, SNPs,
and LNPs is their PEG-driven interaction with SR-BI.
We used flow cytometry to determine the quantity of hHDL, hLDL, CNPs, SNPs, and LNPs in the
supernatant during the incubation with the macrophages. Our goal was to have enough of these
reagents in the cell culture media over the duration of the 24 hours so that the cells could
continually take them up. In each incubation, there was signal for the lipoprotein and NPs at the
24-hour time point (Fig. 2.2B-F). The profiles of the lipoproteins and NPs in the supernatant (not
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taken up by the macrophages) lent insight into the different ways the macrophages take up these
reagents. hHDL and hLDL had similar profiles in the supernatant where a fraction of the flow

Figure 2.11. CNPs, SNPs, and LNP either lower or do not increase cytokines secreted by macrophages. (AAF) Plots of cytokine levels in the media of macrophages that were incubated with either CNPs, SNPs, LNP,
LPS, or PBS (control) for 24 hours. Cytokine levels were normalized by cell count. Then, normalized cytokine
levels for CNPs, SNPs, LNPs, and LPS were divided by cytokine levels for PBS. Each column represents three
separate experiments
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cytometry events had a signal greater than plain media (Fig. 2.2B,C). Short CNPs were taken up
first by macrophages (Fig. 2.2D). This is expected because of the high entropy of long CNPs. SNPs
were the smallest NPs used in this study, thus it was challenging to differentiate them from the
background. LNP signatures most resembled those of hHDL and hLDL as expected (Fig. 2.2F).
These results agree with the differences in macrophage signal after 24 hours (Fig. 2.2G).
Discussion
Overview
NPs have been used primarily to kill cancer cells by delivering cytotoxic agents [200]. Currently
NPs can successfully deliver nucleic acids to target cells (for example, [192]). Therefore, the goal
is to keep the cells alive. Thus, it is now necessary to determine how the recipient cell is affected
by the NPs. For decades, the word “cleared” and its synonyms have been used to describe the
uptake of NPs - regardless of chemistry - by macrophages. Here we show that this phrasing is
likely misleading because PEG-NP micelles (CNPs, SNPs) and PEGylated liposomes (LNPs)
triggered macrophage responses that were very different from those triggered by phagocytosisinducing pathogens - in this case, JRS4 cells. If NPs are “cleared” by macrophages as foreign
bodies, one would also expect an increase in pro-inflammatory signaling. Again, PEG- and lipidbased NPs triggered a completely different response from LPS.
Flow cytometry and fluorescence microscopy
Under both control and autophagy-stimulated conditions, macrophages were treated with hHDL,
hLDL, CNPs, SNPs, LNPs, and JRS4. The results showed that hHDL, hLDL, CNPs, SNPs, and
LNPs lowered autophagosome levels against PBS, starvation, rapamycin, and LPS. JRS4 cells
increased autophagosome abundance. PEG had minimal effect on autophagosome abundance.
hHDL, hLDL, PEG, CNPs, SNPs, and LNPs lowered ROS in DMEM + 10% FBS macrophage
culture conditions. However, only hLDL and SNPs lowered ROS levels raised by starvation. None
of the reagents restored normal ROS levels when rapamycin or LPS were added. As expected JRS4
cells raised ROS levels. We detected no increase in agonist ROS-related transcripts after LNP
addition. CNPs and SNPs had no effect and a lowering effect, respectively, on lysosome pH levels
– a marker of lysosome activity. However, hLDL and LNPs both raised lysosome pH. CNPs,
SNPs, and LNPs all either maintained low levels of secreted cytokines or reduced their levels in
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the media as measured by ELISA. Bearing in mind that conceptual models can never be proved,
only disproved, we show that CNPs, SNPs, and LNPs most likely do not trigger classic phagocytic
or autophagic pathways. Instead, they reduce autophagy and inflammation, and promote
proliferation [183].

Methods
Cell Culture
RAW264.7 macrophages were purchased from ATCC (#TIB-71) and cultured according to the
manufacturer’s instructions. Macrophages were polarized to an M1 phenotype by adding IFNγ.
We used either DMEM + 10% FBS or DMEM (starve) as media for the macrophages for all
experiments.
Lipoprotein, JRS4 cells, and nanoparticles
Human high-density lipoprotein (hHDL) and human low-density lipoprotein (hLDL) were
obtained from Lee Biosolutions (#361-25, #360-10). Samples were diluted to 10 mg/ml in PBS
before administration to macrophages. JRS4 cells were a gift from Dr. Michael Caparon
(Washington University, St. Louis). They were cultured in Todd Hewitt broth (Millipore; #T1438).
PEO56-PBD46 diblock copolymers (filomicelles/CNPs) were synthesized according to the methods
of Ref. 201. PEO132-PBD69 diblock copolymers (spheres/SNPs) were a gift from Dr. Frank S. Bates
(Minnesota). NPs were formed at 10 mg/ml copolymer using film rehydration with phosphate
buffered saline (PBS) as the aqueous buffer as described previously [202]. Nanoparticles were
stained with near-infrared (NIR) dye (Thermo; #D12731) and dialyzed overnight into 1 liter of
PBS at 4C [202]. LNPs were obtained from Formumax Scientific Inc. (#F30204BD22) is a
PEGylated liposome. They are the structural shell of the anti-cancer NP DOXIL [203].
Fluorescence microscopy and flow cytometry
Macrophages were cultured in 96-well plates to confluence. hHDL, hLDL, PEG, CNPs, SNPs, and
LNPs were added at ~200 µg/ml; thus, the weight of material was consistent throughout the
experiments. Rapamycin was added to a final concentration of 250 nM. LPS (Sigma; #L2630) was
added to a final concentration of 250 ng/ml. After the incubation time, the macrophages were
washed with PBS. They were then stained with the appropriate dye for 10 minutes. Washed again
with PBS and imaged on a fluorescence microscope. After imaging, the cells were trypsinized (100
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µl) for 5 minutes at 37C. After incubation, the cells were removed from the well by gentle
pipetting. They were then added to an equal volume of ice-cold 0.5% BSA in PBS. Samples were
run in biological triplicate on an Accuri C6. Cells were gated based on their position in the FSCA vs. SSC-A plot and subsequently by their position in the FSC-H vs. FSC-A plot. For pathogen
vs. CYTO-ID and NP vs. CYTO-ID plots, all cells with signals less than background for either
signal were eliminated. 5,000 data points representing macrophages in the final gate were
randomly chosen by a Mersenne-Twister random number generator. This random selection was
repeated for the other two samples. We used FIJI/ImageJ for image analysis and FlowJo for flow
cytometry gating.
Dyes
JRS4 cells were identified with the DNA marker TOTOTM-3 iodide 642/660 (Thermo; #T3604).
Autophagosome levels were determined using a propriety green fluorescence kit CYTO-ID (Enzo;
#ENZ-KIT175). Lysosomes were identified using Lysotracker (Thermo; #L7528). Macrophage
pH levels were measured by the fluorescence signal of pHrodo (Thermo; #P35380). ROS were
identified by a propietary dye (Sigma; #MAK143)
Statistics
P-values were determined using the Excel t.test() function.
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CHAPTER 3
LIPID NANOPARTICLES TRIGGER mRNA TRANSCRIPTION THAT IS MORE
SIMILAR TO THAT TRIGGERED BY LIPOPROTEIN THAN PATHOGENS AND
ENDOTOXINS.

Introduction
As we were mentioned in the previous chapter, we were examining how macrophages internalized
soft PEG-based NPS, the impacts on the cells over a period of 24 hours, and how NPs ingestion
changed mRNA transcript regulation. We wished to determine the macrophage mRNA transcript
levels of factors involved in autophagy after hHDL, hLDL, JRS4 cell, LPS, and LNP addition to
test our fluorescence microscopy and flow cytometry results. Again, we used IFNγ-polarized
RAW264.7 murine macrophages (hereinafter, macrophages) as our cell model and incubated them
with human high-density lipoprotein (hHDL), human low-density lipoprotein (hLDL), group A
streptococcus pathogens (JRS4 cells), LPS, PEG (MW 6000), PEG-based cylindrical micelles
(CNPs), PEG-based spherical micelles (SNPs), and PEGylated lipid nanoparticles (LNPs). To
investigate if lipoproteins and soft PEG-NPs had similar macrophage responses, hHDL and hLDL
were utilized as controls. The pathogen that induced phagocytosis, inflammation, and autophagy
was tested using JRS4 cells as a positive control. LPS was also used as a positive control for
autophagy and inflammation. Of these reagents, we performed RNA sequencing on macrophages
that were incubated with hHDL, hLDL, JRS4 cells, LPS, LNPs, and PBS (control). we chose 24
hours as the analysis timepoint for all reagents, with the exception of JRS4 cells (3 hours
[(Nakagawa et al., 2004)]).
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The mRNA transcripts of macrophages differed significantly after incubation with hHDL, hLDL,
LNP, and PBS on the one hand and JRS4 cells and LPS on the other. JRS4 cells and LPS triggered
substantial changes in transcripts responsible for pathogen binding and entry, phagocytosis,
autophagy, and inflammation versus PBS controls. LNPs triggered the fewest transcriptome
changes from PBS controls of the five treatments. In chapter two, from fluorescence microscopy
and flow cytometry experiments, hHDL, hLDL, CNPs, SNPs, and LNPs lowered autophagosome
levels against PBS, starvation, rapamycin, and LPS. JRS4 cells increased autophagosome
abundance. PEG had minimal effect on autophagosome abundance. hHDL, hLDL, PEG, CNPs,
SNPs, and LNPs lowered ROS in DMEM + 10% FBS macrophage culture conditions. However,
only hLDL and SNPs lowered ROS levels raised by starvation. None of the reagents restored
normal ROS levels when rapamycin or LPS were added. As expected JRS4 cells raised ROS levels.
We detected no increase in agonist ROS-related transcripts after LNP addition. CNPs and SNPs
had no effect and a lowering effect, respectively, on lysosome pH levels – a marker of lysosome
activity. However, hLDL and LNPs both raised lysosome pH. CNPs, SNPs, and LNPs all either
maintained low levels of secreted cytokines or reduced their levels in the media as measured by
ELISA. mRNA transcripts of pro-inflammatory factors agreed with the ELISA results. By mining
the mRNA transcriptome databases (ImmGen [204]) macrophages incubated with LNPs have
similar profiles to mouse primary cells from lung and spleen but also to mouse stromal cells.
Bearing in mind that conceptual models can never be proved, only disproved, we show that CNPs,
SNPs, and LNPs most likely do not trigger classic phagocytic or autophagic pathways. Instead,
they reduce autophagy and inflammation, and promote proliferation [183].
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Results
We wanted to know how the mRNA transcripts of murine macrophages changed in response to
PEG-based cylindrical micelle NPs (CNPs), PEG-based spherical micelle NPs (SNPs), and
PEGylated lipid vesicle NPs (LNPs) during the course of a 24-hour continuous contact in vitro.
The NPs were used in these experimets has the same characteristics as NPs in chapter two. The
CNPs and SNPs have a PEG exterior and a polybutadiene (PBD) interior. The LNPs are a 56:38:5
molar ratio of hydrogenated soy phosphatidylcholine (HSPC), cholesterol and N-(carbonylmethoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt
(MPEG-DSPE).
LNPs trigger minimal yet unique mRNA transcript changes compared to hHDL and hLDL, and
especially compared to JRS4 cells and LPS
To quantify the macrophage response to our NPs versus their response to lipoproteins, pathogens,
and endotoxin, we incubated macrophages in DMEM + 10% FBS with the addition of either PBS
(24h), hHDL (24h), hLDL (24h), JRS4 cells (3h) [156], LPS (24h), or LNPs (24h). At the indicated
times, we washed the cells with PBS, and extracted the mRNA. We chose LNP as a model NP for
mRNA sequencing because it is more widely used in the clinic than CNPs or SNPs, which are still
in developmental stages. mRNA fold change (FC) values were based from the transcript quantities
of the PBS sample. JRS4 pathogens (2800+,2400-) and LPS (2100+,1700-) triggered the largest FC
values where “+” refers to increased transcript numbers and “-” refers to decreased transcript
numbers (Fig. 3.1A). LNPs triggered about 10-fold fewer changes (188+,155-). hHDL (528+,375-)
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Figure 3.1. mRNA sequencing data show differences among macrophage transcripts that were
incubated with PBS, hHDL, hLDL, JRS4 cells, LPS, and LNPs. (A) Plot of the number of macrophage
transcripts that either increased (red) or decreased (blue) in a statistically valid manner (Q-value < 0.05)
for each of the indicated treatments. Incubation times were 24h except for JRS4 (3h). (B) Principal
component analysis of macrophage transcripts after being incubated with the indicated reagents. (C)
Pearson coefficients of the macrophage transcripts after being incubated with the indicated reagents.
(D) Venn diagrams comparing the similarities and differences of LNPs, hHDL, and hLDL (top)
transcripts, and LNP, JRS4 cells, and LPS transcripts (bottom). (E) LNP, hHDL, and hLDL 49 shared
transcripts. (F) LNP, JRS4, and LPS 70 shared transcripts. The matching macrophage transcripts after
incubation with the other four reagents – hHDL, hLDL, JRS4 cells, LPS - are shown. The scale is from
dark red (log2(FC) = +25) to deep blue (log2(FC) = -25).
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and hLDL (527+,330-) triggered almost identical statistically significant changes in transcript
numbers.
Of the six conditions, principal component analysis (PCA) revealed that the transcripts of
macrophages treated with LPS and JRS4 cells were significantly different from the other four
treatments (Fig. 3.1B). This is a techniqe that reduces the dimentionality of the data sets which
takes advantage of the fact that the images in these datasets share some characteristics. The PCA
values for PBS, hHDL, hLDL, and LNPs formed a cluster away from the JRS4 and LPS clusters.
Thus, the transcript changes triggered by PBS, hHDL, hLDL, and LNPs were relatively similar on
the genome-wide mRNA scale. Pearson coefficients were highest among PBS, hHDL, hLDL, and
LNPs (Fig. 3.1C). They were lower between PBS and JRS4 and lowest between PBS and LPS.
Venn diagrams of hHDL, hLDL, JRS4, LPS, and LNPs mRNA signatures revealed that LNPs,
hHDL, and hLDL shared 49 macrophage transcripts that differed from PBS, and LNPs, JRS4 cells,
and LPS shared 70 macrophage transcripts that differed from PBS (Fig. 3.1D-F). Note the
significant increase in the number of changed macrophage transcript levels after JRS4 and LPS
addition in comparison to LNP, hHDL, and hLDL transcript changes. From these genome-wide
data, we postulate that LNPs trigger transcript-level changes that are more in line with those
triggered by lipoprotein than those triggered by pathogens and endotoxin.
We used bubble plots to visualize the changes in macrophage mRNA levels versus PBS controls
in specific KEGG pathways.(Figure 3.2) hHDL triggered changes in steroid biosynthesis and
sesquiterpenoid and triterpenoid synthesis; hLDL triggered changes in steroid biosynthesis
cholesterol metabolism, NOD-like receptor signaling pathway, and unsaturated fatty acid
biosynthesis; JRS4 cells triggered many changes in surface receptor pathways, the phagosome
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Figure 3.2. KEGG enrichment pathways show differences among macrophage transcripts that were
incubated with PBS, hHDL, hLDL, JRS4 cells, LPS, and LNPs. (A-E) Bubble plots of KEGG
enrichment pathways of macrophage transcripts after being incubated with the indicated reagents.
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pathway, microbial metabolism, glycolysis, and inflammation; LPS triggered changes in similar
pathways as JRS4 cells, one interesting note being the significant impact on the DNA-sensing
pathway even though LPS does not itself have DNA; LNPs triggered almost no significantly
significant changes in these KEGG pathways since transcript levels changes had p-values > 0.05.
Since autophagy is of special note, the transcript changes associated with autophagy (as identified
by the somewhat narrow KEGG definition) were Atg9a (+20), Cflar (+21), Ctsd (n.s.), Itpr1 (-22),
Pik3r2 (-25), Prkcδ (-22), and Supt20 (-21) with log2(FC) values in parentheses. Thus, we see that
most of these autophagy-related transcripts decrease after LNP addition to macrophages. To
understand LNP impact on macrophages we sorted all LNP transcripts by their log2(FC) values
from PBS controls. Differences in the absolute value of the fold change (|FC|) that were less than
5.0 were not considered significant. Comparisons of log2(FC) values that had a Q-value > 0.05
were also not considered significant. We added the corresponding transcripts for the hHDL, hLDL,
JRS4 cells, and LPS experiments to the plots (Fig. 3.3). Instead of discussing the transcripts that
had the largest |FC| values here, we discuss these factors in the sections below specific to cellular
processes important for NP uptake and processing.
We used tree maps to visualize the TPM values of the macrophage transcripts that were incubated
in DMEM + 10% FBS and PBS versus those of the macrophages that were incubated in DMEM
+ 10% FBS and LNPs for 24 hours. The area of each rectangle corresponds to the TPM value for
that transcript. The color of each rectangle corresponds to the log2(FC) value for that transcript
where red indicates an increase and blue indicates a decrease. These TPM values provide insight
into the quantity of each transcript. This information can be used in combination with the log2(FC)
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Figure 3.3. mRNA sequencing data show differences among macrophage transcripts that were
incubated with PBS, hHDL, hLDL, JRS4 cells, LPS, and LNPs. Heat map of macrophage transcripts
where |FC|>5 and Q-value < 0.05 after 24h for the LNP incubation. The matching macrophage
transcripts after incubation with the other four reagents – hHDL, hLDL, JRS4 cells, LPS - are shown.
The scale is from dark red (log2(FC) = +25) to deep blue (log2(FC) = -25).
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data to understand the impact of transcript quantity and change. As a reference, the average β-actin
TPM value across all samples was ~3000. Thus, we see that most of the TPM values of the genes
whose transcripts were changed by LNPs are on a ~100-fold smaller size scale than highly
expressed proteins. The amount of mRNA is an indicator, not a conclusive measure, of cell
function. (The most important factor is the activity of the translated protein. Activity values are
mostly unknown and challenging to quantify.) To further probe this feature of the transcriptomes,
we plotted the TPM values of macrophage transcripts incubated in hHDL, hLDL, JRS4 cells, and
LPS (Fig. 3.4D-G). Interestingly, transcripts responsible for cellular defense such as Ccl3, Ccl4,
Il6rα, Junb [165], Sqstm1, Tlr2, Tnf, and Trem2 had significant basal TPM levels (Fig. 3.4C). Spp1
is highly expressed in cancer cells; thus, its expression is probably due to RAW264.7 macrophages
being an immortalized cell line. Large increases in transcript numbers come mostly from
transcripts that have a ~0 TPM value in the PBS control. Exceptions in the change of large
transcript sets are the striking increases in TPM values of pro-inflammatory genes in macrophages
treated with JRS4 and LPS (Fig. 3.4F,G). Note that the TPM value of Ccl3 after LPS treatment is
almost 10-fold higher than the β-actin TPM value (10500 vs. 3000). There are few blue squares
because those transcripts have TPM values close to 0 after treatment.

Macrophage transcription networks after hHDL, hLDL, JRS4 cell, LPS, and LNP treatment
show significant differences in hubs and connectivity
We determined the effects of hHDL, hLDL, JRS4, LPS, and LNP treatments on known signaling
networks in the STRING database [205]. We entered all transcripts that had log2(|FC|) values > 5
and Q-values < 0.05 into the STRING database. hHDL acted on proteins that are connected
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Figure 3.4. Transcript per million (TPM) values of macrophages after incubation with PBS, hHDL,
hLDL, JRS4 cells, LPS, and LNPs. (A-B) Tree maps of the TPM values of the macrophage genes shown
in Fig. 3.3 for PBS and LNP. (C-G) Tree maps of the TPM values of the major macrophage genes for
PBS, hHDL, hLDL, JRS4 cells, and LPS. The color code is the same as in Fig. 3.3 where red indicates an
increase in log2(FC) and blue indicates a decrease in log 2(FC).
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through Akt3, Nras, Pik3r2, Pik3cd, Ptk2, and Rps6kb1/2 although a network-spanning pathway
does not exist (Fig. 3.5A). The Akt family activates mTOR, thus inhibiting autophagy [206]. Indeed,
HDL inhibits autophagy in experiments [197]. Nras is involved in cell proliferation. Pik3cd is a
lipid kinase that plays widespread roles in cellular physiology including proliferation and
migration. Ptk2 suppresses autophagy [207]. Rps6kb1 is activated by mTORC1 and inhibits IFNγ.
In the hLDL STRING network, Akt3 (+10.7), Chm (+9.6), Crebbp (+20.8), and Ppp2r5c (-7.8)
were located at hubs (Fig. 3.5B). Akt3 elevation agrees with the finding that LDL inhibits
autophagy [208]. Interestingly, Akt3 inhibits pinocytosis of LDL [209]. Chm interacts with Rab
proteins, which have been shown to be important for LDL cholesterol recycling back to the plasma
membrane [210]. Crebbp acts as a circadian transcriptional coactivator which enhances the activity
of the circadian transcriptional activators Npas2-Arntl/Bmal1 and Clock-Arntl/Bmal1
heterodimers [211,212]. Ppp2r5c may play a role in DNA damage-induced inhibition of cell
proliferation; it may also regulate the ERK signaling pathway through ERK dephosphorylation
[213]. Thus, the reduction in its expression would encourage proliferation.
JRS4 cells and LPS trigger complex transcriptome network patterns. JRS4 uptake and processing
triggered a macrophage network with significant clusters of immune regulation (Cd40, Iκbkβ,
Il1α/β, Tnf, Crebbp), GTPase signaling transduction including the Jun-Dmp1 pathway and the
Mapk cascade (Kras, Nras, Pik3cg, Prkcd, Rapgef1, Rgl1, Sos2), ribosome biogenesis (Aatf,
Exosc10, Nat10, Nop56, Wdr75), chromatin organization and histone deacetylase binding (Baz2a,
Chd4, Hist3h2a, Ncor2, Phf21a) factors (Fig. 3.5C). LPS triggered a macrophage network with
significant clusters of nucleotide exchange and chemokine signaling (Arhgef12, Arhgef1, Abr,
Arhgef39, Ect2, Fgd2, Arhgef11, Rhoc), cell cycle (Ccnb2, Cdc20, Espl1, Pttg1, Stag1, Stag2),
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Figure 3.5. STRING database networks of macrophage transcripts after hHDL, hLDL and JRS4 cell
addition. (A-C) Transcripts with |FC| > 5 vales from PBS controls and Q-values < 0.05 were entered
into the STRING database. An interaction score of 0.9 was chosen. Transcripts were grouped into 10 kmeans clusters.
Figure 4. STRING database networks of macrophage transcripts after hHDL, hLDL and JRS4 cell
addition. (A-C) Transcripts with |FC| > 5 vales from PBS controls and Q-values < 0.05 were entered
into the STRING database. An interaction score of 0.9 was chosen. Transcripts were grouped into 10 kmeans clusters.
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and Akt-mTOR signaling and protein production (Akt1, Akt2, Mmp9, Rps6kb1, Rps6kb2, Src)
factors (Fig. 3.6).
LNPs trigger a network with clusters of transcription regulation (Ehmt2, Gatad2b, Mta1, Smad5,
Ubtf, Wiz, Zeb2), protein turnover and histone modification (Ash1l, Ezh2, Hcfc1, Huwe1, Jarid2,
Kmt2c/d, Setd2, Supt20, Taf1, Trrap, Ubap2l), immunity (Adcy7, Cblb, Pde4b), and plasma
membrane dynamics (Dnm2, Prkcζ) factors (Fig. 3.7). By increasing Cblb, LNPs should play an
inhibitory role on BCR, TCR, and Fcγr1. Pik3r2 reduction would decrease the amount of the
signaling lipid PIP3. This could have a number of effects on macrophage phenotype including
modification of the signaling at the plasma membrane. These sequencing data show that
macrophage response to LNPs is uniquely benign even through LNPs are ‘foreign’ objects and the
amount of LNPs taken up by the macrophages is substantial over 24 hours (Fig. 2.2A).

hHDL, hLDL, CNPs, SNPs, and LNPs mRNA transcript changes related to autophagy
We wished to determine the macrophage mRNA transcript levels of factors involved in autophagy
after hHDL, hLDL, JRS4 cell, LPS, and LNP addition to test our fluorescence microscopy and
flow cytometry results. Instead of sorting the transcripts based on the KEGG classification of LNP
data (Fig. 3.2A-E), we present mRNA transcripts that have been shown to be important for
autophagic processes as mined from the literature. mRNA transcripts of the macrophages that were
incubated with hHDL, hLDL, JRS4 cells, LPS, and LNPs revealed that traditional indicators of
autophagy including Atg factors, Becn1 [214], Gabarap, LC3, Ulk1, Rubicon [215], Uvrag, Zfyve1,
and many others, had log2(FC) values that were either not statistically significant or low (Fig.
3.8A).
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Figure 3.6. STRING database networks of macrophage transcripts after LPS addition. (A)
Transcripts with |FC| > 5 vales from PBS controls and Q-values < 0.05 were entered into the
STRING database. An interaction score of 0.9 was chosen. Transcripts were grouped into 10 kmeans clusters.
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Figure 3.7. STRING database networks of macrophage transcripts after LNP addition. (A)
Transcripts with |FC| > 5 vales from PBS controls and Q-values < 0.05 were entered into the STRING
database. An interaction score of 0.9 was chosen. Transcripts were grouped into 10 k-means clusters.
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Figure 3.8. hHDL, hLDL, JRS4 cells, LPS, and LNPs autophagy proteins (A) Heat map of transcrips whose
proteins are involved in autophagy from macrophages that were incubated in the indicated reagents. (B) ) Heat
map of transcrips whose proteins are involved in autophagy from macrophages that were incubated in LPS+LNP
versus macrophages that were incubated in LPS.
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The exceptions were Atg9a for LNPs and Ulk1 for hHDL. hHDL and hLDL raised Akt3 levels,
which inhibits autophagy by activating mTORC2 [206,216,217]; LNPs raised transcripts of the Casp8
homolog, Cflar, which inhibits autophagy [218]. LNPs lowered the log2(FC) values of Itpr1 (-21.5),
Pik3r2 (-25), Prkcζ (-22), and Supt20 (-21). Itpr1 is a receptor that mediates calcium release from
the ER. It was lowered by all reagents; its role is the context of these reagents is unclear. Reduction
of the phosphatidylinositol 3-kinase regulatory subunit beta (Pik3r2) would reduce the amount of
macrophage PIP3. This too does not have a clear cause-effect relationship to NP uptake. The
effects of the reduction of Prkcζ are widespread and depend on macrophage environment. Prkcζ
can function as either a pro-apoptotic or anti-apoptotic protein. Interestingly, it can trigger
apoptosis by activating Mapk11 or Mapk14. Neither factor is increased by LNP addition (not
shown). Prkcζ can promote the interaction of Card9 and Bcl10, which activates NfκB and MAP
kinase p38 pathways [219]. It follows that LNPs have little effect on these pathways as seen
throughout this work. Supt20 is required for starvation-induced Atg9a trafficking during
autophagy. Thus, we see a potential offset in the Atg9a mechanism.
JRS4 cells and LPS triggered selective autophagy through Sqstm1, as expected [156]. The increase
in Rps6kb1/2 by all reagents except LNPs is noteworthy. mTOR1 should activate Rps6kb1/2
leading to IFNγ inhibition and protein synthesis [220]. We also analyzed mRNA from macrophages
that were incubated simultaneously with LPS and LNP for 24 hours. An increase or decrease in
log2(FC) values should indicate an effect of LNPs on macrophages in the presence of LPS versus
LPS alone. Only six genes showed statistically significant changes (Q-value < 0.05). The
combination of LPS+LNP increased Acsl1 (fatty acid oxidation), Itgb3 (phagosome formation),
and Usp25 (deubiquitinase) transcripts; the LPS+LNP combination decreased Mknk1 (HIF-1
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signaling), and Tlr3 (dsRNA recognition) (Fig. 3.8B). An increase in Acsl1 should activate
mTORC1 and thus reduce autophagy [221]. Usp25 is a negative regulator of IL17 signaling [222].
Its increase should decrease inflammation and thus also decrease autophagy [223]. Downregulation
of Mknk1 should reduce the response to cytokines and also should reduce autophagy [224]. Tlr3
reduction should inhibit autophagy [225]. Therefore, we see agreement between fluorescence
microscopy, flow cytometry, and RNA-seq data that LNPs lower macrophage autophagy. It should
be noted that LPS has a much more powerful effect than LNPs on macrophages.

LNPs trigger few changes in M1-derived macrophage surface markers compared to hHDL,
hLDL, JRS4 cells, and LPS
We analyzed ~250 antibodies in the LEGENDscreen panel to determine changes caused by our
reagents after our standard incubation times. JRS4 cells caused significant increases in CD49e,
CD51, CD63, CD83, CD85k, complement receptors, CD98, CD100, CD120b, CD262, CD265,
CD339, CD366, and CD371 mRNA transcripts (Fig. 3.9A). LPS caused significant increases in
CD9, CD14, CD49e, CD59a, CD66a, CD85k, CD98, CD120b, CD229/Ly9, CD255, Galectin-9,
Gl7, and Podoplanin mRNA transcripts (Fig. 3.9A). LNPs did not cause an increase in a single
member of this panel. It is crucial to note that if LNPs triggered significant immune response
changes, we should see these changes in this panel over 24-hour timescales. As a comparison,
larger, non-degradable, micron-sized particles trigger the increase of CD80, CD86, and cytokine
transcript expression in macrophages after uptake [226].
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Figure 3.9. hHDL, hLDL, JRS4 cells, LPS, and LNPs trigger different responses in monocyte cell surface
markers (LEGENDscreen). (A) Heat map of the mRNA transcripts of macrophages incubated in DMEM +
10% FBS and either PBS, hHDL, hLDL, JRS4 cells, LPS, or LNPs.
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LNPs trigger phenotypes similar to murine primary macrophages and stromal cells
We used the ImmGen database to determine how LNPs affected the phenotype of macrophages
compared to available transcript data for ten categories of mouse immune cells [204]. This database
is a repository of scRNA data for murine immune cells harvested from mice of varying genetic
backgrounds. We compared 172 macrophage transcripts with mRNA FC > 5 and Q-value < 0.05
after LNP addition to the FC values of 95 immune cell populations (6 stem cell, 18 B-cell, 37 Tcell, 11 innate lymphocytes, 3 dendritic cell, 9 macrophage, 2 monocyte, 3 granulocyte, 1 mast
cell, 5 stromal). Stem cells, macrophages, and stromal cells had the strongest correlations in
increases in the same genes (Fig. 3.10A, Fig 3.11A). Interestingly, most of the FC values that
increased in our macrophages after LNP addition decreased in the 95 immune cell populations.
Yet, several of the genes increased across the lineages including Sirpα and Tlr3. Several of these
genes form a network around the actions of the Ras activator, Nf1; however; a cohesive map is
elusive. We next compared 151 macrophage transcripts with mRNA FC < 5 and Q-values < 0.05
after LNP addition to the FC values of 95 immune cell populations. This data set has significant
gene identities among the 95 cell conditions (Fig. 3.10B, Fig 3.11B). This means that although
these cells perform distinct tasks in the body, the FC values for this set of genes are remarkably
conserved.

Discussion
General transcript changes
LNPs increased transcript levels of macrophage genes (dark red boxes in Fig. 3.3, far right column)
that span biological processes of chromatin organization, regulation of transcription, regulation of
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Figure 3.10. Comparison of the changes in transcript levels of macrophages incubated with LNP
versus the changes of the same transcripts in ninety-six separate murine immune cells from the
ImmGen database. (A) Box plot of the FC > 5 values of the transcripts shown in Fig. 3.3 in each of the
ninety-six data sets in the ImmGen database. Stem cells (light blue), B cells (dark blue), T cells (purple
and tan), natural killer cells (light purple), dendritic cells (lime), macrophages (green), monocytes
(salmon), granulocytes (red brick), mast cell (cyan), stromal cells (orange). (B) Box plot of the FC < 5
values of the transcripts shown in Fig. 3.3 in each of the ninety-six data sets in the ImmGen database.
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Figure 3.11. Correlated changed transcript with LNP-traeted macrophages incubated with LNP. (A).
The gene names that were identified across the ninety-six data sets where the transcript FC values also
increased. Boxed inset lists the ninety-six data sets. Stem cells (light blue), B cells (dark blue), T cells
(purple and tan), natural killer cells (light purple), dendritic cells (lime), macrophages (green),
monocytes (salmon), granulocytes (red brick), mast cell (cyan), stromal cells (orange). (B) The gene
names that were identified across the ninety-six data sets where the transcript FC values also decreased.
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macromolecule biosynthesis, and regulation of RNA metabolic processes (Baza1, Brca2, Btrc,
Cnot3, Ctcf, Dab2, Ehmt2, Foxp1, Gatad2b, Gon4l, Mbd1, Mitf, Mysm1, Ncoa2, Nfix, Pax6,
Pphln1, Setd2, Sfmbt1, Smad5, Smarca2, Taf1, Tcf25, Tet3, Ubtf, and Zeb2). The functions of these
transcripts are largely connected by Chd3, a component of the NuRD complex required for spindle
organization and centrosome integrity [227]. This indicates that LNPs tend to cause macrophages
proliferation. The vast majority of the protein products of the transcripts having strongly LNPincreased log2(FC) values (Fig. 3.7) are associated with organelles. Only, Arhgef101, Cep295,
Cflar, Fyttd1, Hps5, Plec, Prrc2c, and Stil are strictly cytosolic. The LNP-induced increase of Sirpα
transcripts was unexpected. Sirpα is known to interact with the marker-of-self protein CD47 [228].
This interaction stops phagocytes such as granulocytes and macrophages from engulfing
endogenous cells. Sirpα also limits the respiratory burst in phagocytes [229]. This would reduce
ROS and Cybb levels. Only LPS increased Cybb transcripts (+21.3). Taken in sum, if decreased
Sirpα levels lead to increased phagocytosis, increased Sirpα levels may lead to decreased
phagocytosis.
LNPs decreased transcript levels of macrophage genes (dark blue boxes in Fig. 3.3, far right
column) that span biological processes of transepithelial transport, maintenance of cell polarity,
histone modification, and regulation to external stimuli (Adcy7, Apc, Ash1l, Clasp2, Clock, Fbf1,
Incenp, Itpr1, Jmjd1c, Kdm5c, Macf1, Mapkbp1, Mark2, Med24, Mta1, Numa1, Prkcζ, Ptprs,
Setd3, Slc12a2, Slc23a2, St6gal1, and Tet2). Prkcζ acts downstream of the Par1, Par4, and
Cd36/Gp4 receptors, which are responsible for thrombin binding (Par1, Par2) and free fatty acid
and oxLDL transport (CD36). Prkcζ can promote the interaction of Card9 and Bcl10, which
activates NFκB and MAP kinase p38 pathways [219]. It follows that LNPs have little effect on these
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pathways as seen throughout this work. Polo-like kinase (Plk3) reduction by LNPs (-21.5) should
reduce the phosphorylation of Atf2, Bcl2l1, Hif-1a, and p53 – all factors involved in cell cycle
regulation. Plk3 is also activated in response to ROS production. Adenylate cyclase type 7 (Adcy7)
positively regulates LPS-induced Tnfα production. Thus, LNPs should lower Tnfα levels. Indeed,
Tnf (NM_001278601.1, NM_013693.3) levels were lower in LNP-treated macrophages versus
both JRS4- and LPS-treated macrophages (-6 vs. ~7 and 0 vs. ~5 for the two isoforms,
respectively). LNPs’ decrease of macrophage Rara levels should limit inflammatory response [230].
Reduction of the phosphatidylinositol 3-kinase regulatory subunit beta (Pik3r2) would reduce the
amount of macrophage PIP3. Both hHDL (-25) and LNPs (-25) reduce Pik3r2. The analog Pik3r3
promotes autophagy [231232]. Therefore, Pik3r2 reduction by hHDL and LNPs could partially
explain why these two reagents reduce autophagy. LNPs decreased Agpat1 levels, which converts
lysophosphatidic acid (LPA) to phosphatidic acid (PA). This is one of the first steps in DAG and
TAG synthesis in the ER. The mechanism for the slight decrease in Creb1 transcripts is unclear.
LNPs and LPS downregulates Cblb, Fcγr1, and epidermal growth factor receptor (Egfr) [232]. All
five treatments reduced the transcripts of Birc6, Clasp2, Fanca, Fbf1, Hk1, Itpr1, Jaml, Mark2,
Rbmx, Setd3, Slc23a2, Tcn2, Tet2, and Utrn. Birc6 inhibits apoptosis [233]. Birc6/BRUCE partially
modulates the closure of the autophagosome-lysosome by interacting with Stx17 [234]. Rbmx
promotes Il1β cleavage of Tnfr1 and the release of exosomes. (Exosc10, a component of the
exosome, transcripts go up in all categories except LNP). Hk1 phosphorylates glucose and
activates the Nlrp3 inflammasome [235]. Setd3 is a methyltransferase of actin His73 [236].
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Entry
To elucidate how lipoproteins, JRS4 cells, LPS, and LNPs bind and potentially enter cells, we
determined the mRNA log2(FC) values of ~220 transcripts that are associated with cellular entry
including C-type lectin, Fcγr, Rig-I-like, and TLR pathways. hHDL increased Tlr7 levels (Fig.
3.3). Tlr7 is an endosomal receptor, which is typically associated with binding ssRNA molecules.
Tlr7 interacts with Myd88 causing the activation of Irak1, Irak4, Traf3, Traf6, which in turn
activate NFκB and Irf7 [237,238]. None of these factors had significant FC values after hHDL
incubation with macrophages. This shows that Tlr7 transcript levels may be increased by reasons
different from hHDL binding.
hHDL binds CD36, SR-BI, and LIMP-2. Cd36 levels increased only after LPS treatment.
Scarb1/Srb1 and Limp-2 transcript levels were statistically constant among treatments. These
results were surprising. We expected an increase in these cholesterol and fatty acid transports after
lipoprotein addition. Because PEG binds the CD36 super-family of proteins such as LIMP-2
[160,239] and SR-BI [161], we anticipated the transcripts of these genes would potentially increase
after LNP treatment, but this was not observed. This is slightly at odds with previous studies
showing that PEG NPs interact with SR-BI both in vitro and in vivo – although the amount of
surface-exposed PEG on the NPs in those studies – CNPs and SNPs (100% by mole) - was much
higher than on LNPs (2% by mole).
None of the reagents increased Arp2/3-Scar/WAVE complex transcripts [240]. This complex is
involved in several uptake processes from endocytosis in yeast to phagocytosis in macrophages
[241–243]. Furthermore, none of the reagents increased the transcripts of Nckap1l, which was
recently discovered to be involved in a variety of immune cell processes including phagocytosis
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and migration [242,243]. Interestingly, the hematopoietic-specific HEM1 protein encoded by
Nckap1l controls cytokine equipoise [244]. It is interesting that neither JRS4 cells nor LPS raised
Nckap1l levels. HEM1 loss also blocks mTORC2-dependent Akt phosphorylation, which is a
critical step in insulin/fed response [206]. Blocking this phosphorylation would most likely trigger
autophagy. By not affecting Nckap1l, our reagents should not trigger autophagy by this
mechanism.
Autophagy, innate immunity, and inflammation
LNPs did not increase the number of transcripts of Atg5 [245], Atg12, Atg16l1, cytokines,
chemokines, map kinases, Erk, Ikk [246], NFκB factors, Nod1/2 [171] or Tax1bp [247] versus controls
(Fig. 3.3, Fig. 3.7). In this regard, the macrophage response to LNPs most resembles the
macrophage response to hHDL and hLDL. hHDL and hLDL increased Akt3 (protein kinase B )
transcript levels. Akt activates mTOR, which inhibits autophagy. Activated mTOR1 should
activate p70s6k and Rps6 leading to protein synthesis. Indeed, Rps6k isoforms increased (+6) after
hHDL and hLDL treatments. Akt inhibits Foxo by phosphorylation; this action should increase
cell survival and proliferation. Akt should also increase glucose influx into the macrophage, thus
increasing glycolysis. Activated macrophages favor glycolysis over oxidative respiration. JRS4
and LPS increased Tnf and Traf3 (JRS4) levels but not Fadd levels, meaning that macrophages
seem to favor inflammation over apoptosis after being exposed to JRS4 and LPS. The Traf pathway
should activate Nfκb, but of this protein family only Nfκbiα was increased by JRS4 in our data.
Macrophage activation
Macrophage activation can be grouped into four categories with certain degrees of overlap:
alternative activation (e.g., CD36, Clec10a, Mrc1), antigen presentation (e.g., H2-Aa, H2-Eb1, He-
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Ab1), complement cascade (e.g., C1qc, C1qb), and extracellular matrix receptor-interactions (e.g.,
CD44, Sdc1, Pfn1, Fn1) including cytoskeletal rearrangement and regulation (e.g., Actγ1, Pfn1,
Tmsb4x) [248–250]. Recently, these categories have been found to be subsets of nine stages of
macrophage status post murine infection with Listeria monocytogenes and Heligmosomoides
polygyrus [251]. The nine temporal stages were reduced to four end-point categories: phagocytic
path (e.g., Fcγr1, Fcγr3, Ncf4), oxidative stress path (e.g., Gsr, Prdx5, Txn1), inflammatory path
(e.g., Fcγr1, Ifitm3, Isg20), and remodeling path (e.g., Col1a1, Col3a1, Ddr2). Of these factors,
only Actγ1 and extracellular matrix genes of the Col family were present in our statistically
screened FC data. Additional key signatures of the four macrophage end-point states were
increases in Apoe, Cxcl13, Ctsb, and Pf4, respectively. Apoe was increased by both hHDL and
hLDL and is constant for the other three treatments (Fig. 3.2A). Cxc motif chemokine ligand
transcripts were consistently increased in our data by JRS4 cells and by LPS, but not by hHDL,
hLDL, or LNPs. Ctsb and Pf4 did not appear in our data. Hif1α, Il1α, and Il6 show cyclical
expression patterns over the 24 hours post injections [251]. hHDL, hLDL, and JRS4 cells decreased
Hif1α levels. This would indicate that these three reagents trigger the ‘phagocytic path’ response
[357].
These results show that NPs do not seem to trigger a phagocytic gene regulation response. Further
investigation will involve determining which pathways LNPs and and NPs in general trigger since
we show here that macrophages take up significant quantities of them.

81

Methods
Cell Culture
RAW264.7 macrophages were purchased from ATCC (#TIB-71) and cultured according to the
manufacturer’s instructions. Macrophages were polarized to an M1 phenotype by adding IFNγ.
We used either DMEM + 10% FBS or DMEM (starve) as media for the macrophages for all
experiments.
Lipoprotein, JRS4 cells, and nanoparticles
Human high-density lipoprotein (hHDL) and human low-density lipoprotein (hLDL) were
obtained from Lee Biosolutions (#361-25, #360-10). Samples were diluted to 10 mg/ml in PBS
before administration to macrophages. JRS4 cells were a gift from Dr. Michael Caparon
(Washington University, St. Louis). They were cultured in Todd Hewitt broth (Millipore; #T1438).
PEO56-PBD46 diblock copolymers (filomicelles/CNPs) were synthesized according to the methods
of Ref. 201. PEO132-PBD69 diblock copolymers (spheres/SNPs) were a gift from Dr. Frank S. Bates
(Minnesota). NPs were formed at 10 mg/ml copolymer using film rehydration with phosphate
buffered saline (PBS) as the aqueous buffer as described previously [202]. Nanoparticles were
stained with near-infrared (NIR) dye (Thermo; #D12731) and dialyzed overnight into 1 liter of
PBS at 4C [202]. LNPs were obtained from Formumax Scientific Inc. (#F30204BD22) is a
PEGylated liposome. They are the structural shell of the anti-cancer NP DOXIL [203].
RNA sequencing and analysis
Macrophages were cultured in 6-well plates. At confluence, each well had enough mRNA for
sequencing. Media with or without reagents was removed, macrophages were washed with PBS,
and trypsin digested. The macrophages in trypsin-EDTA (~1 ml) were added to 3 ml of DMEM
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and pelleted at 300 x g for 5 minutes at 4C. Supernatant was removed, and the mRNA was
extracted (Zymo; #R2050). mRNA was shipped on dry ice to BGI for sequencing. Reads were
analyzed using the BGI suite. Each of the five conditions were compared to PBS (control). The
largest changes in log2(FC) in each category were combined into one list. This list was used as the
basis for Fig. 2E. Additional genes that fell under specific cellular functions such as autophagy
were searched for on the BGI website.
Statistics
P-values were determined using the Excel t.test() function.
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